Heterocyles	heterocyle	NNS	O
are	be	VBP	O
important	important	JJ	O
pharmcophores	pharmcophore	NNS	O
and	and	CC	O
have	have	VBP	O
significance	significance	NN	O
to	to	TO	O
create	create	VB	O
privileged	privileged	JJ	O
chemical	chemical	NN	O
structures	structure	NNS	O
possessing	possess	VBG	O
pharmacological	pharmacological	JJ	O
activities	activity	NNS	O
.	.	.	O

Five	five	CD	O
membered	membere	VBN	O
heterocyclic	heterocyclic	NN	O
which	which	WDT	O
incorporate	incorporate	VBP	O
oxygen	oxygen	NN	O
,	,	,	O
nitrogen	nitrogen	NN	O
and	and	CC	O
sulphur	sulphur	NNP	O
are	be	VBP	O
found	find	VBN	O
in	in	IN	O
broad	broad	JJ	O
spectrum	spectrum	NN	O
therapeutic	therapeutic	JJ	O
agents	agent	NNS	O
which	which	WDT	O
have	have	VBP	O
an	an	DT	O
enormous	enormous	JJ	O
significance	significance	NN	O
in	in	IN	O
drug	drug	NN	O
discovery	discovery	NN	O
and	and	CC	O
drug	drug	NN	O
development	development	NN	O
processes	process	VBZ	B
.	.	.	O

Benzothaizole	Benzothaizole	NNP	O
is	be	VBZ	O
a	a	DT	O
fused	fuse	VBN	O
benzoheterocyle	benzoheterocyle	NN	O
which	which	WDT	O
is	be	VBZ	O
present	present	JJ	O
in	in	IN	O
many	many	JJ	O
naturally	naturally	RB	O
occurring	occur	VBG	O
products	product	NNS	O
and	and	CC	O
is	be	VBZ	O
responsible	responsible	JJ	O
for	for	IN	O
the	the	DT	O
medicinal	medicinal	JJ	O
,	,	,	O
pharmacological	pharmacological	JJ	O
and	and	CC	O
pharmaceutical	pharmaceutical	JJ	O
applications	application	NNS	O
of	of	IN	O
such	such	JJ	O
natural	natural	JJ	O
products	product	NNS	B
.	.	.	O

BTA	BTA	NNP	O
is	be	VBZ	O
present	present	JJ	O
in	in	IN	O
terrestrial	terrestrial	JJ	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
marine	marine	JJ	O
compounds	compound	NNS	O
which	which	WDT	O
exhibit	exhibit	VBP	O
various	various	JJ	O
biological	biological	JJ	O
activities	activity	NNS	B
.	.	.	O

The	the	DT	O
BTA	BTA	NNP	O
nucleus	nucleus	NN	O
is	be	VBZ	O
formed	form	VBN	O
by	by	IN	O
the	the	DT	O
fusion	fusion	NN	O
of	of	IN	O
the	the	DT	O
thiazole	thiazole	NN	O
ring	ring	NN	O
with	with	IN	O
a	a	DT	O
benzene	benzene	NN	O
ring	re	VBG	B
.	.	.	O

The	the	DT	O
pharmacological	pharmacological	JJ	O
profile	profile	NN	O
of	of	IN	O
the	the	DT	O
drug	drug	NN	O
used	use	VBN	O
for	for	IN	O
the	the	DT	O
management	management	NN	O
of	of	IN	O
amyotrophic	amyotrophic	JJ	O
lateral	lateral	JJ	O
sclerosis	sclerosis	NN	O
Riluzole	Riluzole	NNP	O
attracted	attract	VBD	O
the	the	DT	O
attention	attention	NN	O
of	of	IN	O
medicinal	medicinal	JJ	O
chemists	chemist	NNS	O
towards	towards	IN	O
biologically	biologically	RB	O
active	active	JJ	O
benzothiazole	benzothiazole	JJ	B
.	.	.	O

Structure	structure	NN	O
of	of	IN	O
riluzole	riluzole	NN	O
,	,	,	O
a	a	DT	O
drug	drug	NN	O
for	for	IN	O
amyotrophic	amyotrophic	JJ	O
lateral	lateral	JJ	O
sclerosis	sclerosis	NN	O
.	.	.	O

The	the	DT	O
BTA	BTA	NNP	O
scaffold	scaffold	NN	O
possesses	possess	VBZ	O
a	a	DT	O
wide	wide	JJ	O
spectrum	spectrum	NN	O
of	of	IN	O
biological	biological	JJ	O
activities	activity	NNS	O
such	such	JJ	O
as	as	IN	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	B
,	,	,	O
fungicidal	fungicidal	JJ	B
,	,	,	O
anti	anti	JJ	O
-	-	JJ	O
diabetic	diabetic	JJ	B
,	,	,	O
analgesic	analgesic	JJ	B
,	,	,	O
anti	anti	JJ	O
-	-	JJ	O
microbial	microbial	JJ	B
,	,	,	O
antitumor	antitumor	NN	B
,	,	,	O
antileishmanial	antileishmanial	JJ	B
,	,	,	O
antheltmintic	antheltmintic	JJ	B
,	,	,	O
antirheumatic	antirheumatic	JJ	B
and	and	CC	O
CNS	cn	VBD	O
depressant	depressant	JJ	B
etc	etc	FW	O
.	.	.	O

BTA	BTA	NNP	O
derivatives	derivative	NNS	O
exhibit	exhibit	VBP	O
remarkable	remarkable	JJ	O
and	and	CC	O
prevalent	prevalent	JJ	O
biological	biological	JJ	O
and	and	CC	O
pharmacological	pharmacological	JJ	O
activities	activity	NNS	O
against	against	IN	O
different	different	JJ	O
types	type	NNS	O
of	of	IN	O
tumours	tumour	NNS	O
and	and	CC	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
such	such	JJ	O
as	as	IN	O
HeLa	HeLa	NNP	O
,	,	,	O
SW480	SW480	NNP	O
,	,	,	O
HepG2	HepG2	NNP	B
,	,	,	O
mammary	mammary	JJ	O
and	and	CC	O
ovarian	ovarian	JJ	O
tumour	tumour	NN	O
cell	cell	NN	O
lines	line	NNS	B
,	,	,	O
colon	colon	NN	O
,	,	,	O
nonsmall	nonsmall	NN	O
-	-	HYPH	O
cell	cell	NN	O
lung	lung	NN	O
and	and	CC	O
breast	breast	NN	O
subpanels	subpanel	NNS	O
cell	cell	NN	O
lines	line	NNS	B
,	,	,	O
and	and	CC	O
HCC	HCC	NNP	B
etc	etc	FW	O
.	.	.	O

Cancer	cancer	NN	O
is	be	VBZ	O
the	the	DT	O
most	most	RBS	O
prominent	prominent	JJ	O
,	,	,	O
notably	notably	RB	O
complex	complex	JJ	O
and	and	CC	O
lethal	lethal	JJ	O
disease	disease	NN	O
which	which	WDT	O
became	become	VBD	O
a	a	DT	O
serious	serious	JJ	O
concern	concern	NN	O
of	of	IN	O
todayâs	todayâs	CD	O
medical	medical	JJ	O
science	science	NN	O
.	.	.	O

It	-PRON-	PRP	O
poses	pose	VBZ	O
a	a	DT	O
great	great	JJ	O
challenge	challenge	NN	O
to	to	IN	O
medical	medical	JJ	O
scientific	scientific	JJ	O
community	community	NN	O
for	for	IN	O
development	development	NN	O
of	of	IN	O
drugs	drug	NNS	O
,	,	,	O
medicines	medicine	NNS	O
and	and	CC	O
procedures	procedure	NNS	O
for	for	IN	O
safer	safe	JJR	O
treatment	treatment	NN	O
and	and	CC	O
cure	cure	NN	O
of	of	IN	O
cancer	cancer	NN	O
disease	disease	NN	B
.	.	.	O

These	these	DT	O
neoplasm	neoplasm	VBP	O
tumour	tumour	NN	O
cells	cell	NNS	O
are	be	VBP	O
diversified	diversified	JJ	O
,	,	,	O
heterogeneous	heterogeneous	JJ	O
cells	cell	NNS	O
with	with	IN	O
rapid	rapid	JJ	O
proliferative	proliferative	JJ	O
properties	property	NNS	O
.	.	.	O

These	these	DT	O
neoplasm	neoplasm	VBP	O
malignant	malignant	JJ	O
tumours	tumour	NNS	O
,	,	,	O
have	have	VBP	O
potential	potential	NN	O
to	to	TO	O
invade	invade	VB	O
or	or	CC	O
spread	spread	VB	O
to	to	IN	O
other	other	JJ	O
parts	part	NNS	O
of	of	IN	O
body	body	NN	O
through	through	IN	O
blood	blood	NN	O
stream	stream	NN	O
and	and	CC	O
lymphatic	lymphatic	JJ	O
system	system	NN	B
.	.	.	O

The	the	DT	O
plethora	plethora	NN	O
of	of	IN	O
research	research	NN	O
mentioned	mention	VBN	O
in	in	IN	O
the	the	DT	O
present	present	JJ	O
review	review	NN	O
of	of	IN	O
last	last	JJ	O
decade	decade	NN	O
on	on	IN	O
anticancer	anticancer	NN	O
potential	potential	NN	O
of	of	IN	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
will	will	MD	O
be	be	VB	O
helpful	helpful	JJ	O
in	in	IN	O
future	future	JJ	O
drug	drug	NN	O
discovery	discovery	NN	O
and	and	CC	O
drug	drug	NN	O
development	development	NN	O
for	for	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
lethal	lethal	JJ	O
cancer	cancer	NN	O
disease	disease	NN	O
.	.	.	O

Aiello	Aiello	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesised	NNP	O
fluorinated	fluorinate	VBD	O
2-aryl	2-aryl	CD	O
benzothiazole	benzothiazole	NN	O
derivatives	derivative	NNS	O
and	and	CC	O
evaluate	evaluate	VB	O
them	-PRON-	PRP	O
for	for	IN	O
anti	anti	JJ	O
-	-	JJ	O
tumour	tumour	JJ	O
activities	activity	NNS	O
against	against	IN	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
such	such	JJ	O
as	as	IN	O
MDA	MDA	NNP	O
-	-	HYPH	O
MB-468	MB-468	NNP	O
and	and	CC	O
MCF-7	mcf-7	JJ	O
cell	cell	NN	O
line	line	NN	O
.	.	.	O

The	the	DT	O
fluorinated	fluorinated	JJ	O
BTA	BTA	NNP	O
derivatives	derivative	VBZ	O
1	1	CD	O
3â(5-fluorobenzothiazol-2-yl)phenol	3â(5-fluorobenzothiazol-2-yl)phenol	CD	O
and	and	CC	O
2	2	CD	O
4â(5-fluorobenzothiazol-2-yl)phenol	4â(5-fluorobenzothiazol-2-yl)phenol	CD	O
having	have	VBG	O
hydroxyl	hydroxyl	NN	O
substituents	substituent	NNS	O
on	on	IN	O
the	the	DT	O
third	third	JJ	O
and	and	CC	O
fourth	fourth	JJ	O
position	position	NN	O
of	of	IN	O
phenyl	phenyl	NNP	O
exhibited	exhibit	VBD	O
the	the	DT	O
best	good	JJS	O
activity	activity	NN	O
having	have	VBG	O
GI50	GI50	NNP	O
values	value	NNS	O
of	of	IN	O
0.57	0.57	CD	O
and	and	CC	O
0.4âÂµM	0.4âÂµM	NNP	O
respectively	respectively	RB	O
against	against	IN	O
MCF	MCF	NNP	O
-	-	HYPH	O
cell	cell	NN	O
line	line	NN	O
as	as	IN	O
compared	compare	VBN	O
to	to	IN	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
containing	contain	VBG	O
alkoxy	alkoxy	JJ	O
,	,	,	O
methyl	methyl	NN	O
sulphonyl	sulphonyl	NN	O
and	and	CC	O
ethyl	ethyl	NN	O
substituents	substituent	NNS	O
on	on	IN	O
the	the	DT	O
benzothiazole	benzothiazole	NN	O
.	.	.	O

Kumbhare	Kumbhare	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

afforded	afford	VBD	O
the	the	DT	O
N	N	NNP	O
-	-	HYPH	O
bis	bis	NN	O
-	-	HYPH	O
benzothiazole	benzothiazole	NN	O
and	and	CC	O
benzothiazolyl	benzothiazolyl	NNP	O
thiocarbamide	thiocarbamide	NN	O
derivatives	derivative	NNS	O
and	and	CC	O
screened	screen	VBN	O
for	for	IN	O
cytotoxic	cytotoxic	JJ	O
activities	activity	NNS	O
against	against	IN	O
two	two	CD	O
human	human	JJ	O
cell	cell	NN	O
lines	line	NNS	O
U-937	U-937	NNP	O
,	,	,	O
THP-1	THP-1	NNP	O
and	and	CC	O
B16-F10	B16-F10	NNP	O
.	.	.	O

The	the	DT	O
thiourea	thiourea	NNP	O
containing	contain	VBG	O
benzothiazole	benzothiazole	JJ	O
derivative	derivative	JJ	O
3	3	CD	O
demonstrated	demonstrate	VBD	O
the	the	DT	O
best	good	JJS	O
antiproliferative	antiproliferative	JJ	O
activity	activity	NN	O
against	against	IN	O
the	the	DT	O
U-937	U-937	NNP	O
cell	cell	NN	O
line	line	NN	O
as	as	IN	O
compared	compare	VBN	O
to	to	IN	O
standard	standard	JJ	O
drug	drug	NN	O
Etoposide	Etoposide	NNP	O
.	.	.	O

The	the	DT	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
compound	compound	NN	O
3	3	CD	O
were	be	VBD	O
higher	high	JJR	O
16.23âÂ±â0.81âÂµM	16.23ââ±â0.81ââµm	CD	O
,	,	,	O
4847.73âÂ±â2.39âÂµM	4847.73ââ±â2.39ââµm	CD	O
and	and	CC	O
34.58âÂ±â1.73âÂµM	34.58ââ±â1.73ââµm	CD	O
as	as	IN	O
compared	compare	VBN	O
to	to	IN	O
standard	standard	JJ	O
compound	compound	NN	O
etoposide	etoposide	NN	O
IC50	IC50	NNP	O
values	value	NNS	O
17.94âÂ±â0.89	17.94ââ±â0.89	CD	O
,	,	,	O
18.69âÂ±â0.94	18.69ââ±â0.94	CD	O
and	and	CC	O
2.16âÂ±â0.11âÂµM	2.16âÂ±â0.11âÂµM	NNP	O
against	against	IN	O
U-937	U-937	NNP	O
,	,	,	O
B16-F10	B16-F10	NNP	O
and	and	CC	O
THP-1	THP-1	NNP	O
cell	cell	NN	O
lines	line	NNS	O
respectively	respectively	RB	B
.	.	.	O

Substituted	substitute	VBN	O
phenols	phenol	NNS	O
containing	contain	VBG	O
a	a	DT	O
flourobenzothiazol	flourobenzothiazol	NN	O
scaffold	scaffold	NN	O
1	1	CD	O
and	and	CC	O
2	2	CD	O
.	.	.	O

Substituted	substitute	VBN	O
thiourea	thiourea	NNP	O
containing	contain	VBG	O
benzothiazole	benzothiazole	JJ	O
derivative	derivative	JJ	O
3	3	CD	O
and	and	CC	O
the	the	DT	O
substituted	substitute	VBN	O
pyrrolidine	pyrrolidine	NN	O
based	base	VBN	O
imidazo	imidazo	NNP	O
benzothiazole	benzothiazole	NNP	O
derivative	derivative	JJ	O
4	4	CD	O
.	.	.	O

Kumbhare	Kumbhare	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
mannich	mannich	NNP	O
base	base	NNP	O
arylimidazo	arylimidazo	NNP	O
derivatives	derivative	NNS	O
containing	contain	VBG	O
benzothiazole	benzothiazole	NN	O
moiety	moiety	NN	O
and	and	CC	O
screened	screen	VBD	O
for	for	IN	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
against	against	IN	O
HepG2	HepG2	NNP	O
,	,	,	O
MCF	MCF	NNP	O
-7	-7	:	O
and	and	CC	O
HeLa	HeLa	NNP	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

All	all	PDT	O
these	these	DT	O
synthesised	synthesise	VBN	O
mannich	mannich	NN	O
bases	basis	NNS	O
BTA	BTA	NNP	O
scaffolds	scaffold	NNS	O
showed	show	VBD	O
cytotoxicity	cytotoxicity	NN	O
against	against	IN	O
all	all	DT	O
tested	test	VBN	O
cell	cell	NN	O
lines	line	NNS	O
but	but	CC	O
the	the	DT	O
pyrrolidine	pyrrolidine	NN	O
based	base	VBN	O
imidazo	imidazo	NNP	O
benzothiazole	benzothiazole	NNP	O
derivative	derivative	JJ	O
4	4	CD	O
demonstrated	demonstrate	VBD	O
specific	specific	JJ	O
features	feature	NNS	O
of	of	IN	O
apoptosis	apoptosis	NN	O
as	as	IN	O
enhancement	enhancement	NN	O
in	in	IN	O
the	the	DT	O
levels	level	NNS	O
of	of	IN	O
caspase-3	caspase-3	NNP	O
.	.	.	O

The	the	DT	O
compound	compound	NN	O
4	4	CD	O
exhibited	exhibit	VBD	O
anti	anti	JJ	O
cancer	cancer	NN	O
activity	activity	NN	O
and	and	CC	O
proved	prove	VBD	O
to	to	TO	O
be	be	VB	O
the	the	DT	O
best	well	RBS	O
antiproliferative	antiproliferative	JJ	O
agent	agent	NN	O
as	as	IN	O
compared	compare	VBN	O
to	to	IN	O
other	other	JJ	O
derivatives	derivative	NNS	O
against	against	IN	O
HepG2	HepG2	NNP	O
,	,	,	O
MCF-7	MCF-7	NNP	O
and	and	CC	O
HeLa	HeLa	NNP	O
cell	cell	NN	O
line	line	NN	O
when	when	WRB	O
screened	screen	VBN	O
at	at	IN	O
4.0âÂµM	4.0ââµm	CD	O
concentrations	concentration	NNS	O
.	.	.	O

The	the	DT	O
SAR	SAR	NNP	O
studies	study	NNS	O
revealed	reveal	VBD	O
that	that	IN	O
the	the	DT	O
incorporation	incorporation	NN	O
of	of	IN	O
fluorine	fluorine	NN	O
atom	atom	NN	O
at	at	IN	O
the	the	DT	O
7th	7th	JJ	O
position	position	NN	O
of	of	IN	O
derivative	derivative	JJ	O
4	4	CD	O
enhanced	enhance	VBD	O
the	the	DT	O
cytotoxicity	cytotoxicity	NN	O
.	.	.	O

The	the	DT	O
compound	compound	NN	O
4	4	CD	O
have	have	VBP	O
potential	potential	NN	O
to	to	TO	O
lead	lead	VB	O
in	in	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
cancer	cancer	NN	O
especially	especially	RB	O
against	against	IN	O
hepatocaricinoma	hepatocaricinoma	NNP	O
.	.	.	O

The	the	DT	O
anticancer	anticancer	NN	O
activity	activity	NN	O
potential	potential	NN	O
of	of	IN	O
BTA	BTA	NNP	O
scaffold	scaffold	NN	O
4	4	CD	O
is	be	VBZ	O
encourging	encourge	VBG	O
for	for	IN	O
the	the	DT	O
development	development	NN	O
of	of	IN	O
new	new	JJ	O
anti	anti	JJ	O
-	-	JJ	O
cancer	cancer	JJ	O
therapeutic	therapeutic	JJ	O
agents	agent	NNS	O
and	and	CC	O
this	this	DT	O
will	will	MD	O
be	be	VB	O
good	good	JJ	O
addition	addition	NN	O
in	in	IN	O
armamentarium	armamentarium	NN	O
that	that	WDT	O
consists	consist	VBZ	O
of	of	IN	O
paclitaxel	paclitaxel	NNP	O
,	,	,	O
cisplatin	cisplatin	NN	O
and	and	CC	O
doxorubicin	doxorubicin	NN	O
drugs	drug	NNS	B
.	.	.	O

Caputo	Caputo	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

afforded	afford	VBD	O
two	two	CD	O
types	type	NNS	O
of	of	IN	O
five	five	CD	O
derivatives	derivative	NNS	O
on	on	IN	O
the	the	DT	O
basis	basis	NN	O
of	of	IN	O
an	an	DT	O
aryl	aryl	NNP	O
amide	amide	NN	O
and	and	CC	O
an	an	DT	O
aryl	aryl	NNP	O
urea	urea	NNP	O
functionalities	functionality	NNS	O
attached	attach	VBN	O
at	at	IN	O
C-2	C-2	NNP	O
of	of	IN	O
benzothiazole	benzothiazole	JJ	O
core	core	NN	O
and	and	CC	O
these	these	DT	O
scaffolds	scaffold	NNS	O
were	be	VBD	O
screened	screen	VBN	O
against	against	IN	O
60	60	CD	O
human	human	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

The	the	DT	O
urea	urea	NNP	O
moiety	moiety	NNP	O
based	base	VBN	O
fluorophenyl	fluorophenyl	NN	O
containing	contain	VBG	O
benzothiazole	benzothiazole	NNP	O
derivative	derivative	JJ	O
4	4	CD	O
and	and	CC	O
cyanophenyl	cyanophenyl	NN	O
containing	contain	VBG	O
benzothiazole	benzothiazole	NNP	O
derivative	derivative	JJ	O
5	5	CD	O
demonstrated	demonstrate	VBD	O
remarkable	remarkable	JJ	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
.	.	.	O

The	the	DT	O
BTA	BTA	NNP	O
derivative	derivative	NN	O
4	4	CD	O
exhibited	exhibit	VBD	O
the	the	DT	O
anticancer	anticancer	NN	O
activity	activity	NN	O
at	at	IN	O
10â5âM	10â5âm	CD	O
against	against	IN	O
different	different	JJ	O
cell	cell	NN	O
lines	line	NNS	O
such	such	JJ	O
as	as	IN	O
leukaemia	leukaemia	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.48	â5.48	NN	O
,	,	,	O
non	non	JJ	O
-	-	JJ	O
small	small	JJ	O
cell	cell	NN	O
lung	lung	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.48	â5.48	NN	O
,	,	,	O
colon	colon	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.51	â5.51	NNP	O
,	,	,	O
central	central	JJ	O
nervous	nervous	JJ	O
system	system	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.49	â5.49	NNP	O
,	,	,	O
melanoma	melanoma	NNP	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.48	â5.48	NNP	O
,	,	,	O
ovarian	ovarian	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.49	â5.49	NNP	O
,	,	,	O
renal	renal	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.53	â5.53	UH	O
,	,	,	O
prostate	prostate	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.50	â5.50	NNP	O
and	and	CC	O
breast	breast	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.56	â5.56	NNP	O
in	in	IN	O
comparison	comparison	NN	O
with	with	IN	O
reference	reference	NN	O
drug	drug	NN	O
5-fluorouracil	5-fluorouracil	CD	O
NSC	NSC	NNP	O
19893	19893	CD	O
.	.	.	O

The	the	DT	O
BTA	BTA	NNP	O
scaffold	scaffold	NN	O
5	5	CD	O
showed	show	VBD	O
remarkable	remarkable	JJ	O
growth	growth	NN	O
inhibitory	inhibitory	NN	O
activities	activity	NNS	O
against	against	IN	O
different	different	JJ	O
human	human	JJ	O
tumour	tumour	NN	O
cell	cell	NN	O
lines	line	NNS	O
such	such	JJ	O
as	as	IN	O
leukaemia	leukaemia	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.93	â5.93	NNP	O
,	,	,	O
non	non	JJ	O
-	-	JJ	O
small	small	JJ	O
cell	cell	NN	O
lung	lung	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â6.0	â6.0	NNP	O
,	,	,	O
colon	colon	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.89	â5.89	NNP	O
,	,	,	O
central	central	JJ	O
nervous	nervous	JJ	O
system	system	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.73	â5.73	NN	O
,	,	,	O
melanoma	melanoma	NNP	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.89	â5.89	NNP	O
,	,	,	O
ovarian	ovarian	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.74	â5.74	NNP	O
,	,	,	O
renal	renal	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.90	â5.90	NNP	O
,	,	,	O
prostate	prostate	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â5.72	â5.72	NNP	O
and	and	CC	O
breast	breast	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
log	log	VB	O
GI50	GI50	NNP	O
value	value	NN	O
â6.0	â6.0	NNP	O
as	as	IN	O
compared	compare	VBN	O
with	with	IN	O
reference	reference	NN	O
drug	drug	NN	O
5-fluorouracil	5-fluorouracil	CD	O
NSC	NSC	NNP	O
19893	19893	CD	O
.	.	.	O

The	the	DT	O
scaffolds	scaffold	NNS	O
4	4	CD	O
and	and	CC	O
5	5	CD	O
showed	show	VBD	O
the	the	DT	O
best	good	JJS	O
anticancer	anticancer	NN	O
therapeutic	therapeutic	JJ	O
potential	potential	NN	O
due	due	IN	O
to	to	IN	O
presence	presence	NN	O
of	of	IN	O
electron	electron	NN	O
with	with	IN	O
drawing	draw	VBG	O
groups	group	NNS	O
on	on	IN	O
para	para	NNP	O
position	position	NN	O
of	of	IN	O
phenyl	phenyl	NN	O
ring	ring	NN	B
.	.	.	O

Substituted	substitute	VBN	O
fluorophenyl	fluorophenyl	NN	O
containing	contain	VBG	O
benzothiazole	benzothiazole	NNP	O
urea	urea	NNP	O
derivative	derivative	NNP	O
5	5	CD	O
and	and	CC	O
2-substituted	2-substituted	CD	O
cyanophenyl	cyanophenyl	NN	O
containing	contain	VBG	O
benzothiazole	benzothiazole	NNP	O
urea	urea	NNP	O
derivatives	derivative	VBZ	O
6	6	CD	O
.	.	.	O

El	El	NNP	O
-	-	HYPH	O
Damasy	Damasy	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBD	O
the	the	DT	O
novel	novel	NN	O
amide	amide	NN	O
and	and	CC	O
urea	urea	NNP	O
based	base	VBN	O
BTA	BTA	NNP	O
series	series	NN	O
of	of	IN	O
20	20	CD	O
sorafenib	sorafenib	NNP	O
analogues	analogue	NNS	O
in	in	IN	O
which	which	WDT	O
the	the	DT	O
pyridylamide	pyridylamide	NN	O
privileged	privileged	JJ	O
functionality	functionality	NN	O
was	be	VBD	O
attached	attach	VBN	O
with	with	IN	O
an	an	DT	O
ether	ether	NN	O
linkage	linkage	NN	O
at	at	IN	O
6-position	6-position	CD	O
of	of	IN	O
the	the	DT	O
BTA	BTA	NNP	O
ring	ring	NN	O
.	.	.	O

A	a	DT	O
selected	select	VBN	O
group	group	NN	O
of	of	IN	O
12	12	CD	O
potent	potent	JJ	O
scaffolds	scaffold	NNS	O
were	be	VBD	O
evaluated	evaluate	VBN	O
and	and	CC	O
appraised	appraise	VBN	O
for	for	IN	O
anti	anti	JJ	O
-	-	JJ	O
proliferative	proliferative	JJ	O
activities	activity	NNS	O
against	against	IN	O
sixty	sixty	CD	O
human	human	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

These	these	DT	O
chlorotrifluoromethyl	chlorotrifluoromethyl	NN	O
phenyl	phenyl	VBP	O
ureido	ureido	JJ	O
picolinamide	picolinamide	NN	O
benzothiazoles	benzothiazole	NNS	O
7	7	CD	O
,	,	,	O
bis	bis	JJ	O
-	-	HYPH	O
trifluoromethyl	trifluoromethyl	NN	O
phenyl	phenyl	NNP	O
ureido	ureido	NNP	O
based	base	VBN	O
picolinamide	picolinamide	NN	O
benzothiazole	benzothiazole	NNP	O
derivative	derivative	JJ	O
8	8	CD	O
and	and	CC	O
dichlorophenyl	dichlorophenyl	NN	O
ureido	ureido	NNP	O
based	base	VBN	O
picolinamide	picolinamide	NN	O
benzothiazoles	benzothiazole	NNS	O
9	9	CD	O
were	be	VBD	O
more	more	RBR	O
potent	potent	JJ	O
in	in	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
renal	renal	JJ	O
cell	cell	NN	O
carcinoma	carcinoma	NN	O
than	than	IN	O
the	the	DT	O
standard	standard	JJ	O
drug	drug	NN	O
sorafenib	sorafenib	NNP	O
,	,	,	O
used	use	VBN	O
for	for	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
such	such	JJ	O
tumours	tumour	NNS	O
.	.	.	O

The	the	DT	O
3,5-bis	3,5-bis	NNP	O
-	-	HYPH	O
trifluoromethylphenylurea	trifluoromethylphenylurea	NNP	O
8	8	CD	O
showed	show	VBD	O
good	good	JJ	O
inhibitory	inhibitory	NN	O
activities	activity	NNS	O
against	against	IN	O
ACHN	ACHN	NNP	O
and	and	CC	O
A-498	A-498	NNP	O
with	with	IN	O
GI50	GI50	NNP	O
values	value	NNS	O
of	of	IN	O
0.542âÂµM	0.542âÂµM	NNP	O
and	and	CC	O
1.02âÂµM	1.02âÂµM	NNP	O
respectively	respectively	RB	O
.	.	.	O

This	this	DT	O
compound	compound	NN	O
also	also	RB	O
possess	possess	VBP	O
efficacy	efficacy	NN	O
against	against	IN	O
UO-31	UO-31	NNP	O
and	and	CC	O
RXF	RXF	NNP	O
393	393	CD	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

The	the	DT	O
derivatives	derivative	NNS	O
7	7	CD	O
and	and	CC	O
9	9	CD	O
because	because	IN	O
of	of	IN	O
3,4-disubstitutedphenyl	3,4-disubstitutedphenyl	CD	O
moiety	moiety	NN	O
,	,	,	O
exhibited	exhibit	VBD	O
excellent	excellent	JJ	O
anti	anti	JJ	O
-	-	JJ	O
proliferative	proliferative	JJ	O
activities	activity	NNS	O
with	with	IN	O
low	low	JJ	O
IG50	IG50	NNP	O
values	value	NNS	O
of	of	IN	O
1.85	1.85	CD	O
,	,	,	O
2.10âÂµM	2.10âÂµM	VBZ	O
against	against	IN	O
RCC	RCC	NNP	O
and	and	CC	O
ACHN	ACHN	NNP	O
cell	cell	NN	O
lines	line	NNS	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
SAR	SAR	NNP	O
study	study	NN	O
revealed	reveal	VBD	O
the	the	DT	O
fact	fact	NN	O
that	that	IN	O
sorafenib	sorafenib	NNP	O
analogues	analogue	NNS	O
possesses	possess	VBZ	O
anti	anti	AFX	O
proliferative	proliferative	JJ	O
activity	activity	NN	O
due	due	IN	O
to	to	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
both	both	CC	O
urea	urea	NNP	O
spacer	spacer	NNP	O
and	and	CC	O
phenyl	phenyl	NN	O
disubstitution	disubstitution	NN	O
.	.	.	O

Compound	Compound	NNP	O
8	8	CD	O
demonstrated	demonstrate	VBD	O
the	the	DT	O
highest	high	JJS	O
CLogP	CLogP	NNP	O
value	value	NN	O
being	be	VBG	O
the	the	DT	O
most	most	RBS	O
lipophilic	lipophilic	JJ	O
and	and	CC	O
potent	potent	JJ	O
derivative	derivative	NN	O
,	,	,	O
in	in	IN	O
the	the	DT	O
low	low	JJ	O
ÂµM	ÂµM	NNP	O
range	range	NN	B
.	.	.	O

Derivative	derivative	JJ	O
7â9	7â9	NNP	O
discussed	discuss	VBD	O
in	in	IN	O
the	the	DT	O
paper	paper	NN	O
.	.	.	O

Ma	Ma	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
containing	contain	VBG	O
an	an	DT	O
ortho	ortho	NNP	O
-	-	HYPH	O
hydroxy	hydroxy	NN	O
-	-	HYPH	O
N	N	NNP	O
-	-	HYPH	O
acyl	acyl	NNP	O
hydrazone	hydrazone	NNP	O
moiety	moiety	NNP	O
for	for	IN	O
antiproliferative	antiproliferative	JJ	O
activities	activity	NNS	O
and	and	CC	O
procaspase-3	procaspase-3	NNP	O
kinase	kinase	VBD	O
activation	activation	NN	O
activities	activity	NNS	O
against	against	IN	O
five	five	CD	O
different	different	JJ	O
cell	cell	NN	O
lines	line	NNS	O
,	,	,	O
namely	namely	RB	O
MDA	MDA	NNP	O
-	-	HYPH	O
MB-231	MB-231	NNP	O
,	,	,	O
MNK-45	mnk-45	JJ	O
,	,	,	O
NCI	NCI	NNP	O
-	-	HYPH	O
H226	H226	NNP	O
,	,	,	O
HT-29	HT-29	NNP	O
and	and	CC	O
SK	SK	NNP	O
-	-	HYPH	O
N	N	NNP	O
-	-	HYPH	O
SH	SH	NNP	O
.	.	.	O

The	the	DT	O
substituted	substituted	JJ	O
2-hydroxybenzylidene	2-hydroxybenzylidene	CD	O
containing	contain	VBG	O
semicarbazide	semicarbazide	NN	O
10	10	CD	O
showed	show	VBD	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
against	against	IN	O
all	all	DT	O
cell	cell	NN	O
lines	line	NNS	O
with	with	IN	O
IC50	IC50	NNP	O
and	and	CC	O
EC50	EC50	NNP	O
values	value	NNS	O
ranging	range	VBG	O
from	from	IN	O
0.24	0.24	CD	O
to	to	IN	O
0.92âÂµM	0.92âÂµM	NNP	O
and	and	CC	O
0.31âÂµM	0.31âÂµM	NNP	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
SAR	SAR	NNP	O
studies	study	NNS	O
revealed	reveal	VBD	O
the	the	DT	O
paharmacological	paharmacological	JJ	O
activities	activity	NNS	O
of	of	IN	O
BTA	BTA	NNP	O
scaffold	scaffold	NN	O
10	10	CD	O
in	in	IN	O
in	in	IN	O
-	-	HYPH	O
vitro	vitro	FW	O
is	be	VBZ	O
due	due	JJ	O
to	to	IN	O
introduction	introduction	NN	O
of	of	IN	O
phenyl	phenyl	NN	O
and	and	CC	O
benzyloxyl	benzyloxyl	NN	O
substitutions	substitution	NNS	B
.	.	.	O

Gabr	Gabr	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

obtained	obtain	VBD	O
hydrazine	hydrazine	NN	O
derivatives	derivative	NNS	O
by	by	IN	O
treating	treat	VBG	O
2-amino-6-fluorobenzothiazole	2-amino-6-fluorobenzothiazole	CD	O
with	with	IN	O
hydrazine	hydrazine	NN	O
hydrate	hydrate	NN	O
which	which	WDT	O
was	be	VBD	O
further	further	RB	O
treated	treat	VBN	O
with	with	IN	O
the	the	DT	O
suitable	suitable	JJ	O
aldehydes	aldehyde	NNS	O
to	to	TO	O
afford	afford	VB	O
27	27	CD	O
different	different	JJ	O
BTA	BTA	NNP	O
Schiff	Schiff	NNP	O
base	base	NN	O
derivatives	derivative	NNS	O
.	.	.	O

These	these	DT	O
derivatives	derivative	NNS	O
were	be	VBD	O
screened	screen	VBN	O
for	for	IN	O
anti	anti	JJ	O
-	-	JJ	O
tumour	tumour	JJ	O
potential	potential	NN	O
against	against	IN	O
Hela	Hela	NNP	O
and	and	CC	O
COS-7	COS-7	NNP	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

The	the	DT	O
hydrazine	hydrazine	NN	O
based	base	VBN	O
benzothiazole	benzothiazole	NN	O
11	11	CD	O
exhibited	exhibit	VBD	O
IC50	IC50	NNP	O
of	of	IN	O
2.41âÂµM	2.41âÂµM	NNP	O
and	and	CC	O
4.31âÂµM	4.31âÂµM	NNP	O
against	against	IN	O
Hela	Hela	NNP	O
and	and	CC	O
COS-7	COS-7	NNP	O
cell	cell	NN	O
lines	line	NNS	O
as	as	IN	O
compared	compare	VBN	O
to	to	TO	O
reference	reference	VB	O
doxorubicin	doxorubicin	NNS	O
having	have	VBG	O
IC50	IC50	NNP	O
2.05âÂµM	2.05âÂµM	NNP	O
and	and	CC	O
3.04âÂµM	3.04âÂµM	NNP	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
SAR	SAR	NNP	O
studies	study	NNS	O
explained	explain	VBD	O
the	the	DT	O
effect	effect	NN	O
of	of	IN	O
various	various	JJ	O
substitutions	substitution	NNS	O
on	on	IN	O
activities	activity	NNS	O
of	of	IN	O
all	all	PDT	O
the	the	DT	O
synthesised	synthesise	VBN	O
derivatives	derivative	NNS	O
.	.	.	O

The	the	DT	O
scaffold	scaffold	JJ	O
present	present	NN	O
in	in	IN	O
11	11	CD	O
has	have	VBZ	O
the	the	DT	O
2â-hydrazino	2â-hydrazino	CD	O
moiety	moiety	NN	O
at	at	IN	O
the	the	DT	O
C-2	C-2	NNP	O
position	position	NN	O
which	which	WDT	O
remarkably	remarkably	RB	O
enhances	enhance	VBZ	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
tumour	tumour	JJ	O
potential	potential	NN	O
,	,	,	O
whereas	whereas	IN	O
replacing	replace	VBG	O
the	the	DT	O
4-hydroxy	4-hydroxy	CD	O
moiety	moiety	NN	O
with	with	IN	O
4-methoxy	4-methoxy	CD	O
decreased	decrease	VBD	O
the	the	DT	O
activities	activity	NNS	O
against	against	IN	O
both	both	DT	O
cell	cell	NN	O
lines	line	NNS	B
.	.	.	O

Junjie	Junjie	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
semicarbazone	semicarbazone	NN	O
containing	contain	VBG	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
by	by	IN	O
the	the	DT	O
reaction	reaction	NN	O
of	of	IN	O
4-nitrobenzyl	4-nitrobenzyl	CD	O
bromide	bromide	NN	O
with	with	IN	O
substituted	substitute	VBN	O
amines	amine	NNS	O
under	under	IN	O
different	different	JJ	O
reaction	reaction	NN	O
conditions	condition	NNS	O
and	and	CC	O
evaluated	evaluate	VBD	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activity	activity	NN	O
against	against	IN	O
four	four	CD	O
different	different	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
line	line	NN	O
such	such	JJ	O
as	as	IN	O
human	human	JJ	O
colon	colon	NN	O
cancer	cancer	NN	O
cells	cell	NNS	O
,	,	,	O
human	human	JJ	O
lung	lung	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
,	,	,	O
non	non	JJ	O
-	-	JJ	O
small	small	JJ	O
cell	cell	NN	O
lung	lung	NN	O
cancer	cancer	NN	O
and	and	CC	O
human	human	JJ	O
breast	breast	NN	O
cancer	cancer	NN	O
.	.	.	O

Among	among	IN	O
these	these	DT	O
derivatives	derivative	NNS	O
,	,	,	O
the	the	DT	O
indole	indole	NN	O
based	base	VBN	O
hydrazine	hydrazine	NNP	O
carboxamide	carboxamide	NNP	O
scaffold	scaffold	NNP	O
12	12	CD	O
showed	show	VBD	O
potent	potent	JJ	O
antitumor	antitumor	NN	O
activity	activity	NN	O
with	with	IN	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
0.015âÂµM	0.015ââµm	NN	O
for	for	IN	O
HT29	HT29	NNP	O
,	,	,	O
0.28âÂµM	0.28âÂµM	NNP	O
for	for	IN	O
H460	H460	NNP	O
,	,	,	O
1.53âÂµM	1.53âÂµM	NNP	O
for	for	IN	O
A549	A549	NNP	O
and	and	CC	O
0.68âÂµM	0.68âÂµM	NNP	O
for	for	IN	O
MDA	MDA	NNP	O
-	-	HYPH	O
MB-231	MB-231	NNP	O
.	.	.	O

The	the	DT	O
structure	structure	NN	O
â	â	NNP	O
activity	activity	NN	O
relationship	relationship	NN	O
explained	explain	VBD	O
that	that	IN	O
compound	compound	NN	O
12	12	CD	O
exhibited	exhibit	VBD	O
the	the	DT	O
highest	high	JJS	O
antitumor	antitumor	NN	O
activity	activity	NN	O
due	due	IN	O
to	to	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
electron	electron	NN	O
withdrawing	withdraw	VBG	O
groups	group	NNS	O
in	in	IN	O
the	the	DT	O
4	4	CD	O
position	position	NN	O
of	of	IN	O
benzyl	benzyl	NN	O
ring	ring	NN	B
.	.	.	O

Indol	Indol	NNP	O
based	base	VBN	O
hydrazine	hydrazine	NN	O
carboxamide	carboxamide	NN	O
benzothiazole	benzothiazole	NNP	O
derivative	derivative	JJ	O
12	12	CD	O
.	.	.	O

Yurttas	Yurttas	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

obtained	obtain	VBD	O
2âBTA	2âbta	CD	O
derivatives	derivative	NNS	O
substituted	substitute	VBN	O
with	with	IN	O
different	different	JJ	O
heterocyclic	heterocyclic	JJ	O
rings	ring	NNS	O
and	and	CC	O
tested	test	VBD	O
their	-PRON-	PRP$	O
antitumor	antitumor	NN	O
potential	potential	NN	O
against	against	IN	O
60	60	CD	O
human	human	JJ	O
tumour	tumour	NN	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

The	the	DT	O
BTA	BTA	NNP	O
derivatives	derivative	VBZ	O
13	13	CD	O
2â(1H	2â(1h	CD	O
-	-	HYPH	O
benzoimidazol-2-ylthio)-N-(4-(benzothiazol-2-yl)-3-chlorophenyl	benzoimidazol-2-ylthio)-N-(4-(benzothiazol-2-yl)-3-chlorophenyl	NNP	O
acetamide	acetamide	NN	O
and	and	CC	O
14	14	CD	O
N-(4-(benzothiazol-2-yl)phenyl)-2-(1-phenyl-1H	N-(4-(benzothiazol-2-yl)phenyl)-2-(1-phenyl-1H	NNP	O
-	-	HYPH	O
benzoimidazol-2-yl	benzoimidazol-2-yl	NNP	O
-	-	HYPH	O
thio)-acetamide	thio)-acetamide	NNP	O
showed	show	VBD	O
remarkable	remarkable	JJ	O
antitumor	antitumor	NN	O
potential	potential	NN	O
against	against	IN	O
different	different	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

The	the	DT	O
heterocylic	heterocylic	JJ	O
substitutions	substitution	NNS	O
affect	affect	VBP	O
the	the	DT	O
activity	activity	NN	O
and	and	CC	O
antitumor	antitumor	NN	O
potential	potential	NN	O
of	of	IN	O
these	these	DT	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
,	,	,	O
with	with	IN	O
derivative	derivative	JJ	O
14	14	CD	O
having	have	VBG	O
comparable	comparable	JJ	O
antitumor	antitumor	NN	O
potential	potential	NN	O
with	with	IN	O
the	the	DT	O
standard	standard	JJ	O
drugs	drug	NNS	O
whereas	whereas	IN	O
derivative	derivative	JJ	O
13	13	CD	O
being	be	VBG	O
less	less	RBR	O
active	active	JJ	O
compared	compare	VBN	O
to	to	IN	O
14	14	CD	O
.	.	.	O

The	the	DT	O
order	order	NN	O
overall	overall	JJ	O
antitumor	antitumor	NN	O
potential	potential	NN	O
of	of	IN	O
2âbenzothiazole	2âbenzothiazole	CD	O
derivatives	derivative	NNS	O
with	with	IN	O
reference	reference	NN	O
to	to	IN	O
the	the	DT	O
heterocyclic	heterocyclic	JJ	O
substitution	substitution	NN	O
was	be	VBD	O
benzimidazole	benzimidazole	NN	O
â¥	â¥	NNP	O
imidazoleâ>âbenzothiazoleâ>âbenzoxazole	imidazoleâ>âbenzothiazoleâ>âbenzoxazole	NNP	B
.	.	.	O

Substituted	substitute	VBN	O
phenyl	phenyl	NNP	O
imidazole	imidazole	NN	O
based	base	VBN	O
benzothiazoles	benzothiazoles	NNP	O
13	13	CD	O
and	and	CC	O
14	14	CD	O
.	.	.	O

Singh	Singh	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
imidazole	imidazole	NN	O
based	base	VBN	O
benzothiazoles	benzothiazole	NNS	O
by	by	IN	O
treatment	treatment	NN	O
of	of	IN	O
substituted	substitute	VBN	O
anilines	aniline	NNS	O
with	with	IN	O
KSCN	KSCN	NNP	O
which	which	WDT	O
afforded	afford	VBD	O
the	the	DT	O
desired	desire	VBN	O
benzothiazole	benzothiazole	NN	O
derivatives	derivative	NNS	O
,	,	,	O
and	and	CC	O
studied	study	VBD	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
.	.	.	O

Compound	Compound	NNP	O
15	15	CD	O
showed	show	VBD	O
excellent	excellent	JJ	O
anticancer	anticancer	NN	O
activity	activity	NN	O
possessing	possess	VBG	O
IC50	IC50	NNP	O
value	value	NN	O
10âÂµM	10ââµm	CD	O
when	when	WRB	O
compared	compare	VBN	O
with	with	IN	O
the	the	DT	O
standard	standard	JJ	O
drug	drug	NN	O
doxorubicin	doxorubicin	NNS	B
.	.	.	O

Imidazole	imidazole	NN	O
based	base	VBN	O
benzothiazole	benzothiazole	NN	O
derivative	derivative	JJ	O
15	15	CD	O
.	.	.	O

Al	Al	NNP	O
-	-	HYPH	O
Soud	Soud	NNP	O
.	.	.	O

etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
incorporating	incorporate	VBG	O
sulphonamide	sulphonamide	NN	O
,	,	,	O
piperazino	piperazino	JJ	O
-	-	HYPH	O
arylsulfonamide	arylsulfonamide	NN	O
and	and	CC	O
arylthiol	arylthiol	NN	O
scaffolds	scaffold	NNS	O
and	and	CC	O
determined	determine	VBD	O
their	-PRON-	PRP$	O
anti	anti	JJ	O
-	-	JJ	O
proliferative	proliferative	JJ	O
potential	potential	NN	O
against	against	IN	O
different	different	JJ	O
cell	cell	NN	O
lines	line	NNS	O
,	,	,	O
such	such	JJ	O
as	as	IN	O
CCRF	CCRF	NNP	O
-	-	HYPH	O
SB	SB	NNP	O
,	,	,	O
DU-145	DU-145	NNP	O
,	,	,	O
HepG-2	hepg-2	CD	O
cell	cell	NN	O
line	line	NN	O
,	,	,	O
WIL-2NS	WIL-2NS	NNP	O
,	,	,	O
MRC-5	MRC-5	NNP	O
,	,	,	O
MCF-7	mcf-7	JJ	O
cell	cell	NN	O
line	line	NN	O
,	,	,	O
MT-4	MT-4	NNP	O
,	,	,	O
SK	SK	NNP	O
-	-	HYPH	O
MES-1	MES-1	NNP	O
cell	cell	NN	O
line	line	NN	O
and	and	CC	O
SK-28	SK-28	NNP	O
cell	cell	NN	O
line	line	NN	O
.	.	.	O

Derivative	derivative	JJ	O
16	16	CD	O
N-(2â(4-(benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl)-4-chloro	n-(2â(4-(benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl)-4-chloro	NN	O
-	-	HYPH	O
benzenesulfonodithioamide	benzenesulfonodithioamide	NN	O
showed	show	VBD	O
antiproliferative	antiproliferative	JJ	O
activity	activity	NN	O
CC50	CC50	NNP	O
=	=	SYM	O
8âÂ±â3âÂµM	8âÂ±â3âÂµM	NNS	O
against	against	IN	O
human	human	NNP	O
derived	derive	VBN	O
DU-145	DU-145	NNP	O
cell	cell	NN	O
line	line	NN	O
whereas	whereas	IN	O
derivative	derivative	JJ	O
17	17	CD	O
N-(2â(4-(benzothiazol-2-yl	N-(2â(4-(benzothiazol-2-yl	NNP	O
piperazin-1-yl)-2-oxoethyl)-2,5-dichloro	piperazin-1-yl)-2-oxoethyl)-2,5-dichloro	NNP	O
benzenesulfonodithio	benzenesulfonodithio	NN	O
-	-	HYPH	O
amide	amide	NN	O
demonstrated	demonstrate	VBD	O
remarkable	remarkable	JJ	O
activities	activity	NNS	O
against	against	IN	O
several	several	JJ	O
human	human	JJ	O
derived	derive	VBN	O
cell	cell	NN	O
lines	line	NNS	O
such	such	JJ	O
as	as	IN	O
HepG2	HepG2	NNP	O
and	and	CC	O
DU-145	DU-145	NNP	O
with	with	IN	O
CC50	CC50	NNP	O
of	of	IN	O
8âÂ±â2âÂµM	8âÂ±â2âÂµM	NNS	O
,	,	,	O
and	and	CC	O
9âÂ±â2âÂµM	9ââ±â2ââµm	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Derivatives	derivative	NNS	O
16	16	CD	O
and	and	CC	O
17	17	CD	O
exhibited	exhibit	VBN	O
atiproliferative	atiproliferative	JJ	O
potential	potential	NN	O
due	due	IN	O
to	to	IN	O
the	the	DT	O
introduction	introduction	NN	O
of	of	IN	O
chloro	chloro	NN	O
and	and	CC	O
dichloro	dichloro	NNP	O
phenyl	phenyl	NNP	O
groups	group	NNS	O
while	while	IN	O
their	-PRON-	PRP$	O
replacement	replacement	NN	O
of	of	IN	O
with	with	IN	O
hydrogen	hydrogen	NN	O
,	,	,	O
methoxy	methoxy	NNP	O
,	,	,	O
nitro	nitro	NNP	O
,	,	,	O
triflouromethyl	triflouromethyl	NNP	O
and	and	CC	O
methyl	methyl	NN	O
groups	group	NNS	O
lead	lead	VBP	O
to	to	IN	O
a	a	DT	O
decrease	decrease	NN	O
in	in	IN	O
the	the	DT	O
antiproliferative	antiproliferative	JJ	O
potential	potential	NN	O
of	of	IN	O
BTA	BTA	NNP	O
derivatives	derivative	VBZ	B
.	.	.	O

Di-/monochlorobenzenesulfonamide	di-/monochlorobenzenesulfonamide	IN	O
based	base	VBN	O
piperazine	piperazine	NN	O
benzothiazoles	benzothiazole	NNS	O
derivative	derivative	JJ	O
16	16	CD	O
and	and	CC	O
17	17	CD	O
.	.	.	O

Gurdal	gurdal	NN	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBD	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
which	which	WDT	O
incorporate	incorporate	VBP	O
piperazine	piperazine	NN	O
moieties	moiety	NNS	O
and	and	CC	O
evaluated	evaluate	VBD	O
their	-PRON-	PRP$	O
cytotoxicity	cytotoxicity	NN	O
against	against	IN	O
different	different	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
such	such	JJ	O
as	as	IN	O
HUH-7	HUH-7	NNP	O
,	,	,	O
MCF-7	MCF-7	NNP	O
and	and	CC	O
HCT-116	hct-116	UH	O
.	.	.	O

GI50	gi50	NN	O
values	value	NNS	O
of	of	IN	O
these	these	DT	O
derivatives	derivative	NNS	O
indicated	indicate	VBD	O
that	that	IN	O
all	all	DT	O
compounds	compound	NNS	O
exhibited	exhibit	VBD	O
good	good	JJ	O
potential	potential	NN	O
against	against	IN	O
the	the	DT	O
aforementioned	aforementioned	JJ	O
cell	cell	NN	O
lines	line	NNS	O
but	but	CC	O
the	the	DT	O
pyridine	pyridine	NNP	O
containing	contain	VBG	O
derivative	derivative	JJ	O
18	18	CD	O
had	have	VBD	O
a	a	DT	O
remarkable	remarkable	JJ	O
cytotoxic	cytotoxic	NN	O
activity	activity	NN	O
with	with	IN	O
GI50	GI50	NNP	O
value	value	NN	O
7.9âÂµM	7.9ââµm	CD	O
,	,	,	O
9.2âÂµM	9.2ââµm	CD	O
and	and	CC	O
3.1âÂµM	3.1ââµm	CD	O
for	for	IN	O
HCT-116	HCT-116	NNP	O
,	,	,	O
MCF-7	MCF-7	NNP	O
and	and	CC	O
HUH-7	HUH-7	NNP	O
respectively	respectively	RB	O
.	.	.	O

Apoptosis	apoptosis	NN	O
caused	cause	VBN	O
by	by	IN	O
this	this	DT	O
derivative	derivative	NN	O
during	during	IN	O
cell	cell	NN	O
cycle	cycle	NN	O
arrest	arrest	NN	O
at	at	IN	O
subG1	subG1	``	O
phase	phase	NN	O
was	be	VBD	O
confirmed	confirm	VBN	O
by	by	IN	O
Hoechst	Hoechst	NNP	O
staining	staining	JJ	O
and	and	CC	O
fluorescence	fluorescence	NN	O
activated	activate	VBN	O
cell	cell	NN	O
sorting	sort	VBG	O
analysis	analysis	NN	B
.	.	.	O

Pyridine	pyridine	JJ	O
conataining	conataine	VBG	O
piperazine	piperazine	NN	O
benzothiazole	benzothiazole	NN	O
derivative	derivative	JJ	O
18	18	CD	O
.	.	.	O

Akhtar	Akhtar	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBD	O
BTA	BTA	NNP	O
and	and	CC	O
1,3,4-oxadiazole-2-thione	1,3,4-oxadiazole-2-thione	CD	O
derivatives	derivative	NNS	O
and	and	CC	O
determined	determine	VBD	O
their	-PRON-	PRP$	O
antitumor	antitumor	NN	O
potential	potential	NN	O
in	in	IN	O
in	in	IN	O
-	-	HYPH	O
vitro	vitro	FW	O
against	against	IN	O
different	different	JJ	O
tumour	tumour	NN	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

BTA	BTA	NNP	O
derivatives	derivative	VBZ	O
19	19	CD	O
N-(benzothiazol-2-yl)-2â(5-(1âpropyl)-1,3,4-oxadiazol-2-ylthio)acetamide	n-(benzothiazol-2-yl)-2â(5-(1âpropyl)-1,3,4-oxadiazol-2-ylthio)acetamide	CD	O
and	and	CC	O
20	20	CD	O
N-(benzothiazol-2-yl)-2â(5-(1âethyl)-1,3,4-oxadiazol-2-ylthio	N-(benzothiazol-2-yl)-2â(5-(1âethyl)-1,3,4-oxadiazol-2-ylthio	NNP	O
acetamide	acetamide	NN	O
exhibited	exhibit	VBD	O
remarkable	remarkable	JJ	O
activities	activity	NNS	O
against	against	IN	O
CCRF	CCRF	NNP	O
-	-	HYPH	O
CEM	CEM	NNP	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

The	the	DT	O
CC50	CC50	NNP	O
values	value	NNS	O
of	of	IN	O
compounds	compound	NNS	O
19	19	CD	O
and	and	CC	O
20	20	CD	O
CC50	CC50	NNP	O
=	=	SYM	O
12âÂ±â2âÂµM	12ââ±â2ââµm	CD	O
and	and	CC	O
8âÂ±â1âÂµM	8âÂ±â1âÂµM	NNS	O
respectively	respectively	RB	O
were	be	VBD	O
comparable	comparable	JJ	O
to	to	IN	O
the	the	DT	O
standard	standard	JJ	O
drug	drug	NN	O
Doxorubicin	Doxorubicin	NNP	O
.	.	.	O

The	the	DT	O
replacement	replacement	NN	O
of	of	IN	O
the	the	DT	O
chloro	chloro	NN	O
moiety	moiety	NN	O
with	with	IN	O
bromo	bromo	NNP	O
in	in	IN	O
the	the	DT	O
hybrid	hybrid	JJ	O
structures	structure	NNS	O
of	of	IN	O
19	19	CD	O
and	and	CC	O
20	20	CD	O
decreased	decrease	VBD	O
their	-PRON-	PRP$	O
anti	anti	JJ	O
-	-	JJ	O
tumour	tumour	JJ	O
potential	potential	JJ	B
.	.	.	O

Oxadiazole	oxadiazole	NN	O
based	base	VBN	O
acetamide	acetamide	NN	O
benzothiazole	benzothiazole	NNP	O
derivatives	derivative	VBZ	O
19	19	CD	O
and	and	CC	O
20	20	CD	O
.	.	.	O

Saeed	Saeed	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
benzothiazole	benzothiazole	NNP	O
moiety	moiety	NNP	O
based	base	VBN	O
thiourea	thiourea	NNP	O
derivatives	derivative	NNS	O
.	.	.	O

These	these	DT	O
novel	novel	JJ	O
derivatives	derivative	NNS	O
were	be	VBD	O
tested	test	VBN	O
for	for	IN	O
anticancer	anticancer	NN	O
potential	potential	NN	O
against	against	IN	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
MCF-7	MCF-7	NNP	O
and	and	CC	O
HeLa	HeLa	NNP	O
cells	cell	NNS	O
.	.	.	O

The	the	DT	O
MTT	MTT	NNP	O
assay	assay	NN	O
indicated	indicate	VBD	O
that	that	IN	O
the	the	DT	O
thiophene	thiophene	NN	O
based	base	VBN	O
acetamide	acetamide	NNP	O
benzothiazole	benzothiazole	NNP	O
derivatives	derivative	VBZ	O
21	21	CD	O
,	,	,	O
morpholine	morpholine	NNP	O
based	base	VBN	O
thiourea	thiourea	NNP	O
aminobenzothiazole	aminobenzothiazole	NNP	O
derivative	derivative	NNP	O
22	22	CD	O
and	and	CC	O
morpholine	morpholine	NNP	O
based	base	VBN	O
thiourea	thiourea	NNP	O
bromobenzothiazole	bromobenzothiazole	NNP	O
23	23	CD	O
were	be	VBD	O
potent	potent	JJ	O
anticancer	anticancer	NN	O
agents	agent	NNS	O
having	have	VBG	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
24.15	24.15	CD	O
,	,	,	O
26.43	26.43	CD	O
and	and	CC	O
18.10âÂµM	18.10ââµm	CD	O
against	against	IN	O
MCF-7	mcf-7	JJ	O
cell	cell	NN	O
line	line	NN	O
,	,	,	O
and	and	CC	O
of	of	IN	O
46.46	46.46	CD	O
,	,	,	O
45.29	45.29	CD	O
and	and	CC	O
38.85âÂµM	38.85ââµm	CD	O
against	against	IN	O
HeLa	HeLa	NNP	O
cells	cell	NNS	O
lines	line	NNS	O
respectively	respectively	RB	B
.	.	.	O

Morpholine	Morpholine	NNP	O
based	base	VBN	O
thiourea	thiourea	NNP	O
bromobenzothiazoles	bromobenzothiazole	VBZ	O
22â24	22â24	CD	O
.	.	.	O

Lei	Lei	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

obtained	obtain	VBD	O
the	the	DT	O
morpholine	morpholine	NNP	O
based	base	VBN	O
acetamide	acetamide	NN	O
benzothiazole	benzothiazole	NNP	O
derivative	derivative	JJ	O
24	24	CD	O
by	by	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
morpholine	morpholine	NNP	O
with	with	IN	O
2-chloroacetyl	2-chloroacetyl	CD	O
chloride	chloride	NN	O
and	and	CC	O
studied	study	VBD	O
its	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activity	activity	NN	O
against	against	IN	O
HCC	HCC	NNP	O
cell	cell	NN	O
lines	line	NNS	O
HepG2	HepG2	NNP	O
and	and	CC	O
Bel7402	Bel7402	NNP	O
,	,	,	O
reporting	report	VBG	O
IC50	IC50	NNP	O
value	value	NN	O
for	for	IN	O
HepG2	HepG2	NNP	O
and	and	CC	O
Bel7402	Bel7402	NNP	O
in	in	IN	O
the	the	DT	O
millimolar	millimolar	JJ	O
range	range	NN	B
.	.	.	O

.	.	.	O

Morpholine	Morpholine	NNP	O
based	base	VBN	O
acetamide	acetamide	NN	O
benzothiazole	benzothiazole	NNP	O
24	24	CD	O
.	.	.	O

Racane	Racane	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

obtained	obtain	VBD	O
the	the	DT	O
furyl	furyl	NN	O
and	and	CC	O
thienyl	thienyl	NNP	O
based	base	VBN	O
diamidino	diamidino	JJ	O
substituted	substitute	VBN	O
derivatives	derivative	NNS	O
of	of	IN	O
phenyl	phenyl	NN	O
-	-	HYPH	O
BTA	BTA	NNP	O
and	and	CC	O
screened	screen	VBD	O
them	-PRON-	PRP	O
for	for	IN	O
antiproliferative	antiproliferative	JJ	O
activities	activity	NNS	O
against	against	IN	O
different	different	JJ	O
tumour	tumour	NN	O
cell	cell	NN	O
line	line	NN	O
inÂ	inâ	JJ	O
vitro	vitro	FW	O
.	.	.	O

Derivative	derivative	JJ	O
25	25	CD	O
and	and	CC	O
26	26	CD	O
exhibited	exhibit	VBN	O
low	low	JJ	O
cytotoxic	cytotoxic	JJ	O
effects	effect	NNS	O
on	on	IN	O
normal	normal	JJ	O
human	human	JJ	O
fibroblasts	fibroblast	NNS	O
and	and	CC	O
strong	strong	JJ	O
antiproliferative	antiproliferative	JJ	O
effects	effect	NNS	O
on	on	IN	O
MiaPaCa-2	MiaPaCa-2	NNP	O
and	and	CC	O
MCF-7	MCF-7	NNP	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

The	the	DT	O
experimental	experimental	JJ	O
data	datum	NNS	O
indicated	indicate	VBD	O
that	that	IN	O
the	the	DT	O
benzothiazole	benzothiazole	NN	O
derivatives	derivative	NNS	O
having	have	VBG	O
thiophene	thiophene	NN	O
and	and	CC	O
imidazole	imidazole	NN	O
substitions	substition	NNS	O
possessed	possess	VBD	O
interesting	interesting	JJ	O
antiproliferative	antiproliferative	JJ	O
activities	activity	NNS	B
.	.	.	O

Sekar	Sekar	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
and	and	CC	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
of	of	IN	O
six	six	CD	O
noval	noval	NN	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
.	.	.	O

All	all	DT	O
derivatives	derivative	NNS	O
exhibited	exhibit	VBD	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
from	from	IN	O
a	a	DT	O
high	high	NN	O
to	to	IN	O
a	a	DT	O
moderate	moderate	JJ	O
activity	activity	NN	O
level	level	NN	O
with	with	IN	O
the	the	DT	O
substituted	substitute	VBN	O
thiadiazole	thiadiazole	NNP	O
flourobenzothiazole	flourobenzothiazole	JJ	O
27	27	CD	O
and	and	CC	O
methoxybenzothiazole	methoxybenzothiazole	RB	O
28	28	CD	O
showing	show	VBG	O
the	the	DT	O
best	good	JJS	O
anti	anti	JJ	O
-	-	JJ	O
cancer	cancer	JJ	O
potential	potential	NN	O
due	due	IN	O
to	to	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
highly	highly	RB	O
electronative	electronative	JJ	O
and	and	CC	O
electron	electron	NN	O
denoting	denoting	NN	O
pharmacophores	pharmacophore	NNS	B
.	.	.	O

Substituted	substitute	VBN	O
thiadiazole	thiadiazole	NN	O
based	base	VBN	O
BTAs	BTAs	NNP	O
27	27	CD	O
and	and	CC	O
28	28	CD	O
.	.	.	O

Shi	shi	NN	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBD	O
20	20	CD	O
BTA-2-thiol	bta-2-thiol	NN	O
derivatives	derivative	NNS	O
and	and	CC	O
investigated	investigate	VBD	O
their	-PRON-	PRP$	O
anti	anti	JJ	O
-	-	JJ	O
tumour	tumour	JJ	O
potential	potential	NN	O
against	against	IN	O
different	different	JJ	O
cell	cell	NN	O
lines	line	NNS	O
such	such	JJ	O
as	as	IN	O
SW480	SW480	NNP	O
,	,	,	O
HeLa	HeLa	NNP	O
,	,	,	O
A549	A549	NNP	O
,	,	,	O
HCT-116	hct-116	UH	O
,	,	,	O
HepG2	HepG2	NNP	O
and	and	CC	O
SKRB-3	SKRB-3	VBD	O
breast	breast	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
line	line	NN	O
.	.	.	O

The	the	DT	O
substituted	substitute	VBN	O
bromopyridine	bromopyridine	NN	O
acetamide	acetamide	NN	O
benzothiazole	benzothiazole	NNP	O
derivative	derivative	JJ	O
29	29	CD	O
showed	show	VBD	O
potent	potent	JJ	O
antitumor	antitumor	NN	O
activity	activity	NN	O
against	against	IN	O
SKRB-3	SKRB-3	NNP	O
,	,	,	O
SW620	SW620	NNP	O
,	,	,	O
A549	A549	NNP	O
and	and	CC	O
HepG2	HepG2	NNP	O
cell	cell	NN	O
lines	line	NNS	O
with	with	IN	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
1.2ânM	1.2ânm	CD	O
,	,	,	O
4.3ânM	4.3ânm	CD	O
,	,	,	O
44ânM	44ânm	CD	O
and	and	CC	O
48ânM	48ânm	CD	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Apoptosis	apoptosis	NN	O
was	be	VBD	O
the	the	DT	O
mechanism	mechanism	NN	O
of	of	IN	O
cell	cell	NN	O
death	death	NN	O
and	and	CC	O
was	be	VBD	O
concentration	concentration	NN	O
dependent	dependent	JJ	O
in	in	IN	O
HepaG2	HepaG2	NNS	O
cells	cell	NNS	O
.	.	.	O

These	these	DT	O
results	result	NNS	O
indicated	indicate	VBD	O
that	that	IN	O
BTA-2-thiols	bta-2-thiol	NNS	O
exhibit	exhibit	VB	O
broad	broad	JJ	O
spectrum	spectrum	NN	O
anti	anti	JJ	O
-	-	JJ	O
cancer	cancer	JJ	O
activities	activity	NNS	O
which	which	WDT	O
are	be	VBP	O
worth	worth	JJ	O
to	to	TO	O
be	be	VB	O
further	further	RB	O
investigated	investigate	VBN	B
.	.	.	O

Substituted	substitute	VBN	O
bromopyridine	bromopyridine	NN	O
based	base	VBN	O
acetamide	acetamide	NN	O
benzothiazole	benzothiazole	NNP	O
derivative	derivative	JJ	O
29	29	CD	O
.	.	.	O

Xuejiao	Xuejiao	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
a	a	DT	O
substituted	substitute	VBN	O
pyridine	pyridine	NN	O
based	base	VBN	O
acetamide	acetamide	NN	O
BTA	BTA	NNP	O
derivative	derivative	NN	O
30	30	CD	O
and	and	CC	O
screened	screen	VBD	O
its	-PRON-	PRP$	O
anti	anti	JJ	O
-	-	JJ	O
cancer	cancer	JJ	O
activity	activity	NN	O
both	both	CC	O
inÂ	inâ	JJ	O
vitro	vitro	FW	O
and	and	CC	O
in	in	IN	O
vivo	vivo	NNP	O
.	.	.	O

Derivative	derivative	JJ	O
30	30	CD	O
demonstrated	demonstrate	VBD	O
anti	anti	JJ	O
-	-	JJ	O
proliferative	proliferative	JJ	O
activities	activity	NNS	O
against	against	IN	O
a	a	DT	O
wide	wide	JJ	O
spectrum	spectrum	NN	O
of	of	IN	O
human	human	JJ	O
cell	cell	NN	O
lines	line	NNS	O
and	and	CC	O
induced	induce	VBD	O
the	the	DT	O
mitochondrial	mitochondrial	NN	O
apoptotic	apoptotic	JJ	O
pathway	pathway	NN	O
in	in	IN	O
HepaG2	HepaG2	NNP	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

The	the	DT	O
BTA	BTA	NNP	O
scaffold	scaffold	NN	O
30	30	CD	O
proved	prove	VBD	O
to	to	TO	O
be	be	VB	O
a	a	DT	O
promising	promising	JJ	O
candidate	candidate	NN	O
for	for	IN	O
cancer	cancer	NN	O
chemotherapy	chemotherapy	NN	B
.	.	.	O

Substituted	substitute	VBN	O
pyridine	pyridine	JJ	O
based	base	VBN	O
acetamide	acetamide	NN	O
benzothiazole	benzothiazole	NNP	O
30	30	CD	O
and	and	CC	O
pyridine	pyridine	NNP	O
containing	contain	VBG	O
pyrimidine	pyrimidine	NN	O
benzothiazole	benzothiazole	NN	O
31	31	CD	O
.	.	.	O

Kamal	Kamal	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
novel	novel	JJ	O
phenyl	phenyl	NNP	O
pyridopyrimidinones	pyridopyrimidinone	NNS	O
based	base	VBN	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
which	which	WDT	O
were	be	VBD	O
examined	examine	VBN	O
against	against	IN	O
four	four	CD	O
different	different	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
such	such	JJ	O
as	as	IN	O
ME-180	ME-180	NNP	O
,	,	,	O
DU-145	DU-145	NNP	O
,	,	,	O
MCF-7	MCF-7	NNP	O
and	and	CC	O
B-16	b-16	CD	O
.	.	.	O

The	the	DT	O
pyridine	pyridine	JJ	O
containing	contain	VBG	O
pyrimidine	pyrimidine	NN	O
benzothiazole	benzothiazole	NNP	O
31	31	CD	O
exhibited	exhibit	VBD	O
interesting	interesting	JJ	O
cytotoxicity	cytotoxicity	NN	O
with	with	IN	O
IC50	IC50	NNP	O
value	value	NN	O
of	of	IN	O
4.01âÂµM	4.01âÂµM	NNP	O
against	against	IN	O
ME-180	ME-180	NNP	B
.	.	.	O

Gabr	Gabr	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
and	and	CC	O
evaluation	evaluation	NN	O
of	of	IN	O
novel	novel	JJ	O
BTA	BTA	NNP	O
scaffolds	scaffold	NNS	O
against	against	IN	O
60	60	CD	O
tumour	tumour	NN	O
cell	cell	NN	O
lines	line	NNS	O
at	at	IN	O
a	a	DT	O
single	single	JJ	O
dose	dose	NN	O
of	of	IN	O
10âÂµM.	10ââµm.	CD	O
The	the	DT	O
best	good	JJS	O
derivatives	derivative	NNS	O
were	be	VBD	O
32	32	CD	O
and	and	CC	O
33	33	CD	O
,	,	,	O
which	which	WDT	O
were	be	VBD	O
further	further	RB	O
screened	screen	VBN	O
at	at	IN	O
5	5	CD	O
doses	dose	NNS	O
.	.	.	O

These	these	DT	O
derivatives	derivative	NNS	O
demonstrated	demonstrate	VBD	O
interesting	interesting	JJ	O
anticancer	anticancer	NN	O
activity	activity	NN	O
at	at	IN	O
micro	micro	NNP	O
molar	molar	NNP	O
and	and	CC	O
sub	sub	VB	O
micro	micro	JJ	O
molar	molar	JJ	O
concentrations	concentration	NNS	O
,	,	,	O
against	against	IN	O
all	all	DT	O
sixty	sixty	CD	O
tumour	tumour	NN	O
cell	cell	NN	O
lines	line	NNS	O
with	with	IN	O
GI50	GI50	NNP	O
in	in	IN	O
the	the	DT	O
low	low	JJ	O
micro	micro	JJ	O
molar	molar	JJ	O
or	or	CC	O
submicromolar	submicromolar	JJ	O
range	range	NN	O
.	.	.	O

The	the	DT	O
SAR	SAR	NNP	O
study	study	NN	O
revealed	reveal	VBD	O
that	that	IN	O
introduction	introduction	NN	O
of	of	IN	O
the	the	DT	O
pyrazole	pyrazole	NNP	O
moiety	moiety	NN	O
significantly	significantly	RB	O
enhanced	enhance	VBD	O
the	the	DT	O
antitumor	antitumor	NN	O
activity	activity	NN	O
of	of	IN	O
both	both	DT	O
derivatives	derivative	NNS	O
.	.	.	O

Furthermore	furthermore	RB	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
2-hydroxy	2-hydroxy	CD	O
ester	ester	NN	O
and	and	CC	O
3-oxopyrazole	3-oxopyrazole	CD	O
within	within	IN	O
the	the	DT	O
pyrimidine	pyrimidine	NNP	O
moiety	moiety	NN	O
increased	increase	VBD	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
tumour	tumour	JJ	O
activities	activity	NNS	O
of	of	IN	O
both	both	DT	O
derivatives	derivative	NNS	O
.	.	.	O

The	the	DT	O
simple	simple	JJ	O
BTA	BTA	NNP	O
scafolds	scafold	VBZ	O
having	have	VBG	O
pyrazole	pyrazole	NN	O
functionalities	functionality	NNS	O
were	be	VBD	O
more	more	RBR	O
potent	potent	JJ	O
against	against	IN	O
different	different	JJ	O
cell	cell	NN	O
lines	line	NNS	O
as	as	IN	O
compared	compare	VBN	O
to	to	IN	O
derivatives	derivative	NNS	O
having	have	VBG	O
the	the	DT	O
pyrazole	pyrazole	NN	O
ring	ring	NN	O
within	within	IN	O
a	a	DT	O
pyrimidine	pyrimidine	JJ	O
moiety	moiety	NN	B
.	.	.	O

Kambhare	Kambhare	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBD	O
the	the	DT	O
isoxazole	isoxazole	JJ	O
pyrimidine	pyrimidine	NN	O
based	base	VBN	O
BTAs	bta	NNS	O
and	and	CC	O
evaluated	evaluate	VBD	O
them	-PRON-	PRP	O
for	for	IN	O
anticancer	anticancer	NN	O
activity	activity	NN	O
by	by	IN	O
the	the	DT	O
MTT	MTT	NNP	O
assay	assay	NN	O
against	against	IN	O
different	different	JJ	O
cell	cell	NN	O
lines	line	NNS	O
such	such	JJ	O
as	as	IN	O
A549	A549	NNP	O
,	,	,	O
Colo205	colo205	NN	O
,	,	,	O
MCF-7	MCF-7	NNP	O
and	and	CC	O
U937	U937	NNP	O
cell	cell	NN	O
lines	line	NNS	O
,	,	,	O
in	in	IN	O
comparison	comparison	NN	O
with	with	IN	O
the	the	DT	O
standard	standard	JJ	O
drug	drug	NN	O
etoposide	etoposide	NN	O
.	.	.	O

The	the	DT	O
pyridine	pyridine	JJ	O
containing	contain	VBG	O
pyrimidine	pyrimidine	NN	O
derivative	derivative	JJ	O
34	34	CD	O
demonstrated	demonstrate	VBN	O
good	good	JJ	O
anti	anti	JJ	O
-	-	JJ	O
cancer	cancer	JJ	O
potential	potential	NN	O
with	with	IN	O
IC50	IC50	NNP	O
value	value	NN	O
5.04âÂµM	5.04âÂµM	NNP	O
against	against	IN	O
colo205	colo205	NNP	O
,	,	,	O
13.9âÂµM	13.9ââµm	CD	O
against	against	IN	O
U937	U937	NNP	O
,	,	,	O
30.67âÂµM	30.67ââµm	CD	O
against	against	IN	O
MCF-7	MCF-7	NNP	O
and	and	CC	O
30.45âÂµM	30.45ââµm	CD	O
against	against	IN	O
A549	A549	NNP	O
cell	cell	NN	O
lines	line	NNS	O
when	when	WRB	O
compared	compare	VBN	O
with	with	IN	O
standard	standard	JJ	O
drug	drug	NN	O
etoposide	etoposide	NN	O
.	.	.	O

The	the	DT	O
scaffold	scaffold	JJ	O
34	34	CD	O
activated	activate	VBN	O
p53	p53	NN	O
or	or	CC	O
TP53	TP53	NNP	O
pathways	pathway	NNS	O
,	,	,	O
which	which	WDT	O
regulate	regulate	VBP	O
the	the	DT	O
equilibrium	equilibrium	NN	O
between	between	IN	O
apoptosis	apoptosis	NN	O
and	and	CC	O
cell	cell	NN	O
proliferation	proliferation	NN	O
.	.	.	O

The	the	DT	O
SAR	SAR	NNP	O
explained	explain	VBD	O
that	that	IN	O
the	the	DT	O
maximum	maximum	JJ	O
cytotoxicity	cytotoxicity	NN	O
of	of	IN	O
derivative	derivative	JJ	O
34	34	CD	O
against	against	IN	O
colon	colon	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
line	line	NN	O
was	be	VBD	O
due	due	JJ	O
to	to	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
methoxy	methoxy	NN	O
group	group	NN	O
âOCH3	âoch3	UH	O
in	in	IN	O
the	the	DT	O
phenyl	phenyl	NNP	B
.	.	.	O

Structure	structure	NN	O
of	of	IN	O
pyrimidine	pyrimidine	NN	O
based	base	VBN	O
isoxazole	isoxazole	NNP	O
derivative	derivative	JJ	O
34	34	CD	O
.	.	.	O

Waghmare	Waghmare	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
substituted	substitute	VBN	O
pyrimidine	pyrimidine	NN	O
containing	contain	VBG	O
benzothiazole	benzothiazole	JJ	O
derivative	derivative	JJ	O
35	35	CD	O
by	by	IN	O
refluxing	refluxe	VBG	O
BTAs	bta	NNS	O
with	with	IN	O
bis	bis	JJ	O
-	-	HYPH	O
methylthio	methylthio	NNP	O
methylene	methylene	NNP	O
malononitrile	malononitrile	NN	O
,	,	,	O
and	and	CC	O
tested	test	VBD	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activity	activity	NN	O
against	against	IN	O
18	18	CD	O
different	different	JJ	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

The	the	DT	O
scaffold	scaffold	JJ	O
35	35	CD	O
possessed	possess	VBD	O
excellent	excellent	JJ	O
anticancer	anticancer	NN	O
activity	activity	NN	O
with	with	IN	O
a	a	DT	O
good	good	JJ	O
percentage	percentage	NN	O
of	of	IN	O
growth	growth	NN	O
inhibition	inhibition	NN	O
against	against	IN	O
lung	lung	NN	O
cancer	cancer	NN	O
,	,	,	O
breast	breast	NN	O
cancer	cancer	NN	O
and	and	CC	O
renal	renal	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

The	the	DT	O
good	good	JJ	O
anticancer	anticancer	NN	O
activity	activity	NN	O
of	of	IN	O
derivative	derivative	JJ	O
35	35	CD	O
is	be	VBZ	O
due	due	JJ	O
to	to	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
two	two	CD	O
methyl	methyl	NN	O
and	and	CC	O
one	one	CD	O
SCH3	SCH3	NNP	O
groups	group	NNS	O
in	in	IN	O
its	-PRON-	PRP$	O
structure	structure	NN	B
.	.	.	O

Pyrimidine	Pyrimidine	NNP	O
based	base	VBD	O
benzothiazole	benzothiazole	JJ	O
derivative	derivative	JJ	O
35	35	CD	O
and	and	CC	O
36	36	CD	O
.	.	.	O

Caleta	Caleta	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBD	O
cyano	cyano	NNP	O
and	and	CC	O
amidinobenzothiazole	amidinobenzothiazole	NNP	O
substituted	substitute	VBD	O
anilins	anilin	NNS	O
which	which	WDT	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
2-bromo-6-cyanobenzothiazole	2-bromo-6-cyanobenzothiazole	CD	O
under	under	IN	O
specific	specific	JJ	O
reaction	reaction	NN	O
conditions	condition	NNS	O
to	to	TO	O
afford	afford	VB	O
compounds	compound	NNS	O
which	which	WDT	O
have	have	VBP	O
been	be	VBN	O
studied	study	VBN	O
for	for	IN	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activity	activity	NN	O
against	against	IN	O
6	6	CD	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
such	such	JJ	O
as	as	IN	O
laryngeal	laryngeal	JJ	O
carcinoma	carcinoma	NN	O
,	,	,	O
breast	breast	NN	O
carcinoma	carcinoma	NN	O
,	,	,	O
cervical	cervical	JJ	O
carcinoma	carcinoma	NN	O
,	,	,	O
pancreatic	pancreatic	JJ	O
carcinoma	carcinoma	NN	O
,	,	,	O
colon	colon	NN	O
carcinoma	carcinoma	NN	O
,	,	,	O
lung	lung	NN	O
carcinoma	carcinoma	NN	O
,	,	,	O
and	and	CC	O
diploid	diploid	NN	O
fibroblasts	fibroblast	NNS	O
.	.	.	O

Among	among	IN	O
them	-PRON-	PRP	O
,	,	,	O
the	the	DT	O
pyrimidine	pyrimidine	NN	O
based	base	VBN	O
carbonitrile	carbonitrile	JJ	O
benzothiazole	benzothiazole	NNP	O
derivative	derivative	JJ	O
36	36	CD	O
showed	show	VBD	O
potent	potent	JJ	O
activity	activity	NN	O
against	against	IN	O
all	all	DT	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
used	use	VBN	O
in	in	IN	O
the	the	DT	O
study	study	NN	B
.	.	.	O

Osmaniye	osmaniye	NN	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

prepared	prepare	VBD	O
BTA	BTA	NNP	O
acylhydrazone	acylhydrazone	NN	O
using	use	VBG	O
4-fluorobenzaldehyde	4-fluorobenzaldehyde	CD	O
refluxed	refluxe	VBN	O
with	with	IN	O
substituted	substitute	VBN	O
amines	amine	NNS	O
,	,	,	O
to	to	TO	O
afford	afford	VB	O
the	the	DT	O
desired	desire	VBN	O
derivatives	derivative	NNS	O
and	and	CC	O
studied	study	VBD	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
against	against	IN	O
rat	rat	NNP	O
brain	brain	NNP	O
glioma	glioma	NNP	O
cell	cell	NN	O
line	line	NN	O
,	,	,	O
human	human	JJ	O
lung	lung	NN	O
adenocarcinoma	adenocarcinoma	NN	O
epithelial	epithelial	JJ	O
cell	cell	NN	O
line	line	NN	O
,	,	,	O
human	human	JJ	O
breast	breast	NN	O
adenocarcinoma	adenocarcinoma	NN	O
cell	cell	NN	O
line	line	NN	O
,	,	,	O
human	human	JJ	O
colorectal	colorectal	JJ	O
adenocarcinoma	adenocarcinoma	NN	O
cell	cell	NN	O
line	line	NN	O
and	and	CC	O
mouse	mouse	NN	O
embryo	embryo	NN	O
fibroblast	fibroblast	NN	O
cell	cell	NN	O
line	line	NN	O
.	.	.	O

The	the	DT	O
piperidine	piperidine	NN	O
based	base	VBN	O
acetohydrazide	acetohydrazide	RB	O
derivative	derivative	JJ	O
37	37	CD	O
showed	show	VBD	O
modest	modest	JJ	O
activity	activity	NN	O
having	have	VBG	O
IC50	IC50	NNP	O
value	value	NN	O
1â<âmM	1â<âmm	CD	O
,	,	,	O
0.03âmM	0.03âmm	CD	O
,	,	,	O
0.10âmM	0.10âmm	NN	O
,	,	,	O
0.30âmM	0.30âmm	NN	O
and	and	CC	O
1	1	CD	O
<	<	XX	O
mM	mM	NNP	O
for	for	IN	O
A549	A549	NNP	O
,	,	,	O
HT-29	HT-29	NNP	O
,	,	,	O
MCF-7	MCF-7	NNP	O
,	,	,	O
C6	c6	NN	O
,	,	,	O
and	and	CC	O
NIH3T3	NIH3T3	NNP	O
cell	cell	NN	O
lines	line	NNS	O
respectively	respectively	RB	O
against	against	IN	O
reference	reference	NN	O
drug	drug	NN	O
cisplatin	cisplatin	NN	B
.	.	.	O

Piperidine	Piperidine	NNP	O
based	base	VBN	O
acetohydrazide	acetohydrazide	NNP	O
benzothiazole	benzothiazole	NNP	O
37	37	CD	O
.	.	.	O

Lad	Lad	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
methylsulfonyl	methylsulfonyl	NNP	O
benzothiazoles	benzothiazoles	NNP	O
,	,	,	O
obtained	obtain	VBN	O
from	from	IN	O
5-ethoxybenzothiazol-2-amine	5-ethoxybenzothiazol-2-amine	CD	O
which	which	WDT	O
were	be	VBD	O
tested	test	VBN	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
.	.	.	O

Among	among	IN	O
these	these	DT	O
derivatives	derivative	NNS	O
,	,	,	O
the	the	DT	O
nitrophenyl	nitrophenyl	NN	O
sulphonamide	sulphonamide	NN	O
based	base	VBN	O
methylsulfonyl	methylsulfonyl	NNP	O
benzothiazole	benzothiazole	NNP	O
38	38	CD	O
and	and	CC	O
ter	ter	NN	O
-	-	HYPH	O
butyl	butyl	NN	O
sulphonamide	sulphonamide	NN	O
based	base	VBN	O
methylsulfonyl	methylsulfonyl	NNP	O
benzothiazole	benzothiazole	NNP	O
39	39	CD	O
exhibited	exhibit	VBD	O
the	the	DT	O
best	good	JJS	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
against	against	IN	O
HeLa	HeLa	NNP	O
cell	cell	NN	O
line	line	NN	O
with	with	IN	O
the	the	DT	O
IG50	IG50	NNP	O
value	value	NN	O
of	of	IN	O
0.22âÂµM	0.22âÂµM	NNP	O
and	and	CC	O
0.6âÂµM	0.6ââµm	CD	O
respectively	respectively	RB	B
.	.	.	O

Sulphonamide	sulphonamide	NN	O
based	base	VBN	O
methylsulfonyl	methylsulfonyl	NN	O
benzothiazoles	benzothiazole	VBZ	O
38	38	CD	O
and	and	CC	O
39	39	CD	O
.	.	.	O

Sadhasivam	Sadhasivam	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
2	2	CD	O
,	,	,	O
6-disubstituted	6-disubstituted	CD	O
-	-	HYPH	O
BTA	BTA	NNP	O
by	by	IN	O
reaction	reaction	NN	O
of	of	IN	O
2-amino-6-nitrobenzothiazole	2-amino-6-nitrobenzothiazole	CD	O
and	and	CC	O
acetic	acetic	JJ	O
anhydride	anhydride	NN	O
and	and	CC	O
studied	study	VBD	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activity	activity	NN	O
against	against	IN	O
three	three	CD	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
MCF-7	MCF-7	NNP	O
,	,	,	O
HeLa	HeLa	NNP	O
and	and	CC	O
MG63	MG63	NNP	O
The	the	DT	O
sulphonamide	sulphonamide	NN	O
scaffold	scaffold	NN	O
based	base	VBN	O
BTA	BTA	NNP	O
40	40	CD	O
exhibited	exhibit	VBD	O
modest	modest	JJ	O
anti	anti	JJ	O
-	-	JJ	O
cancer	cancer	JJ	O
activity	activity	NN	O
with	with	IN	O
IC50	IC50	NNP	O
of	of	IN	O
34.5âÂµM	34.5ââµm	CD	O
for	for	IN	O
MCF-7	MCF-7	NNP	O
,	,	,	O
44.15âÂµM	44.15ââµm	CD	O
for	for	IN	O
HeLa	HeLa	NNP	O
and	and	CC	O
36.1âÂµM	36.1ââµm	CD	O
for	for	IN	O
the	the	DT	O
MG63	MG63	NNP	B
.	.	.	O

Secondary	secondary	JJ	O
sulphonamide	sulphonamide	NN	O
based	base	VBN	O
acetamide	acetamide	NN	O
benzothiazole	benzothiazole	NNP	O
40	40	CD	O
.	.	.	O

Wang	Wang	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBD	O
and	and	CC	O
evaluated	evaluate	VBD	O
24	24	CD	O
benzothiazole-2-thiol	benzothiazole-2-thiol	NNP	O
derivatives	derivative	NNS	O
for	for	IN	O
antiproliferative	antiproliferative	JJ	O
activities	activity	NNS	O
against	against	IN	O
different	different	JJ	O
human	human	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
such	such	JJ	O
as	as	IN	O
A549	A549	NNP	O
,	,	,	O
HCT-116	hct-116	UH	O
,	,	,	O
SW620	SW620	NNP	O
,	,	,	O
SW480	SW480	NNP	O
,	,	,	O
MDA	MDA	NNP	O
-	-	HYPH	O
MB-468	MB-468	NNP	O
,	,	,	O
SKRB-3	SKRB-3	VBD	O
,	,	,	O
HeLa	HeLa	NNP	O
,	,	,	O
SKOV-3	skov-3	NN	O
,	,	,	O
PC-3	PC-3	NNP	O
,	,	,	O
BxPC-3	bxpc-3	ADD	O
,	,	,	O
A431	A431	NNP	O
and	and	CC	O
A375	A375	NNP	O
.	.	.	O

Some	some	DT	O
derivatives	derivative	NNS	O
exhibited	exhibit	VBD	O
better	well	JJR	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
as	as	IN	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
standard	standard	JJ	O
drug	drug	NN	O
cisplatin	cisplatin	NN	O
.	.	.	O

The	the	DT	O
substituted	substitute	VBN	O
methoxybenzamide	methoxybenzamide	NN	O
benzothiazole	benzothiazole	NN	O
41	41	CD	O
and	and	CC	O
the	the	DT	O
substituted	substitute	VBN	O
chloromethylbenzamide	chloromethylbenzamide	NN	O
benzothiazole	benzothiazole	NNP	O
42	42	CD	O
showed	show	VBD	O
good	good	JJ	O
anti	anti	JJ	O
-	-	JJ	O
tumour	tumour	JJ	O
potential	potential	JJ	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
,	,	,	O
with	with	IN	O
IC50	IC50	NNP	O
values	value	NNS	O
ranging	range	VBG	O
from	from	IN	O
1.1âÂµM	1.1ââµm	CD	O
to	to	IN	O
8.8âÂµM.	8.8ââµm.	CD	O
The	the	DT	O
introduction	introduction	NN	O
of	of	IN	O
chloromethyl	chloromethyl	NN	O
and	and	CC	O
methoxy	methoxy	JJ	O
functionalities	functionality	NNS	O
in	in	IN	O
compounds	compound	NNS	O
41	41	CD	O
and	and	CC	O
42	42	CD	O
increased	increase	VBD	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activity	activity	NN	O
compared	compare	VBN	O
to	to	IN	O
other	other	JJ	O
synthesised	synthesise	VBN	O
analogs	analog	VBZ	B
.	.	.	O

Substituted	substitute	VBN	O
methoxybenzamide	methoxybenzamide	NN	O
based	base	VBN	O
benzothiazole	benzothiazole	JJ	O
derivative	derivative	JJ	O
41	41	CD	O
and	and	CC	O
chloromethylbenzamide	chloromethylbenzamide	NN	O
based	base	VBN	O
benzothiazole	benzothiazole	NNP	O
42	42	CD	O
.	.	.	O

Bolelli	Bolelli	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBD	O
2-substituted	2-substituted	CD	O
benzothiazoles	benzothiazole	NNS	O
by	by	IN	O
the	the	DT	O
reaction	reaction	NN	O
of	of	IN	O
carboxylic	carboxylic	JJ	O
acid	acid	NN	O
with	with	IN	O
thionyl	thionyl	NN	O
chloride	chloride	NN	O
which	which	WDT	O
afforded	afford	VBD	O
acyl	acyl	NNP	O
chlorides	chloride	NNS	O
,	,	,	O
further	further	RB	O
treated	treat	VBN	O
with	with	IN	O
substituted	substitute	VBN	O
benzothiazole	benzothiazole	NN	O
to	to	TO	O
give	give	VB	O
2-substituted	2-substituted	CD	O
benzothiazoles	benzothiazole	NNS	O
,	,	,	O
which	which	WDT	O
were	be	VBD	O
studied	study	VBN	O
for	for	IN	O
their	-PRON-	PRP$	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
against	against	IN	O
human	human	JJ	O
glutathione	glutathione	NN	O
transferases	transferase	NNS	O
.	.	.	O

The	the	DT	O
benzamide	benzamide	NN	O
benzothiazole	benzothiazole	NN	O
derivative	derivative	JJ	O
43	43	CD	O
and	and	CC	O
benzamide	benzamide	VB	O
methylbenzothiazole	methylbenzothiazole	NNP	O
44	44	CD	O
showed	show	VBD	O
potent	potent	JJ	O
hGSTP1	hgstp1	CD	O
-	-	SYM	O
1	1	CD	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
,	,	,	O
useful	useful	JJ	O
in	in	IN	O
cancer	cancer	NN	O
chemotherapy	chemotherapy	NN	O
.	.	.	O

The	the	DT	O
SAR	SAR	NNP	O
studies	study	NNS	O
pinpointed	pinpoint	VBD	O
that	that	IN	O
both	both	CC	O
these	these	DT	O
scaffold	scaffold	NN	O
showed	show	VBD	O
effective	effective	JJ	O
inhibition	inhibition	NN	O
due	due	IN	O
to	to	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
para	para	NN	O
-	-	HYPH	O
substitutions	substitution	NNS	O
on	on	IN	O
the	the	DT	O
phenyl	phenyl	NN	O
ring	ring	NN	O
of	of	IN	O
the	the	DT	O
benzamide	benzamide	NN	O
group	group	NN	B
.	.	.	O

Corbo	corbo	VB	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
19	19	CD	O
derivatives	derivative	NNS	O
of	of	IN	O
benzamide	benzamide	NN	O
based	base	VBN	O
BTAs	bta	NNS	O
by	by	IN	O
the	the	DT	O
reaction	reaction	NN	O
of	of	IN	O
substituted	substitute	VBN	O
aniline	aniline	NN	O
,	,	,	O
potassium	potassium	NN	O
thiocyante	thiocyante	NNP	O
and	and	CC	O
bromine	bromine	NNP	O
,	,	,	O
which	which	WDT	O
afforded	afford	VBD	O
substituted	substitute	VBN	O
compounds	compound	NNS	O
which	which	WDT	O
were	be	VBD	O
tested	test	VBN	O
for	for	IN	O
anti	anti	JJ	O
-	-	JJ	O
proliferative	proliferative	JJ	O
activity	activity	NN	O
against	against	IN	O
MCF-7	MCF-7	NNP	O
and	and	CC	O
HepG2	HepG2	NNP	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

The	the	DT	O
substituted	substitute	VBN	O
diflourobenzamide	diflourobenzamide	NN	O
containing	contain	VBG	O
benzothiazole	benzothiazole	JJ	O
45	45	CD	O
proved	prove	VBD	O
to	to	TO	O
be	be	VB	O
a	a	DT	O
potent	potent	JJ	O
anti	anti	JJ	O
-	-	JJ	O
proliferative	proliferative	JJ	O
compound	compound	NN	O
with	with	IN	O
the	the	DT	O
percentual	percentual	JJ	O
inhibition	inhibition	NN	O
of	of	IN	O
64âÂ±â2	64ââ±â2	CD	O
ÂµM	ÂµM	NNS	O
for	for	IN	O
MCF-7	mcf-7	JJ	O
cell	cell	NN	O
line	line	NN	O
and	and	CC	O
of	of	IN	O
64âÂ±â6	64ââ±â6	CD	O
ÂµM	ÂµM	NNS	O
for	for	IN	O
HepG2	HepG2	NNP	O
cell	cell	NN	O
line	line	NN	B
.	.	.	O

Substituted	substitute	VBN	O
difluorobenzamide	difluorobenzamide	NN	O
BTA	BTA	NNP	O
derivative	derivative	JJ	O
45	45	CD	O
.	.	.	O

Abdelgawad	Abdelgawad	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBD	O
quinolone	quinolone	NNP	O
based	base	VBN	O
benzothiazole	benzothiazole	NN	O
derivatives	derivative	NNS	O
by	by	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
substituted	substitute	VBN	O
benzothiazoles	benzothiazole	NNS	O
with	with	IN	O
aromatic	aromatic	JJ	O
aldehydes	aldehyde	NNS	O
.	.	.	O

The	the	DT	O
nitrobenzylidene	nitrobenzylidene	NN	O
containing	contain	VBG	O
quinolone	quinolone	NNP	O
derivative	derivative	JJ	O
46	46	CD	O
and	and	CC	O
the	the	DT	O
hydroxybenzylidine	hydroxybenzylidine	NN	O
containing	contain	VBG	O
derivative	derivative	JJ	O
47	47	CD	O
showed	show	VBD	O
antitumor	antitumor	NN	O
activities	activity	NNS	O
against	against	IN	O
the	the	DT	O
MCF-7	mcf-7	JJ	O
cell	cell	NN	O
line	line	NN	O
,	,	,	O
having	have	VBG	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
0.058âÂµM	0.058âÂµM	NNP	O
and	and	CC	O
0.052âÂµM	0.052âÂµM	NNP	O
,	,	,	O
respectively	respectively	RB	B
.	.	.	O

Hydroxybenzylidine	Hydroxybenzylidine	NNP	O
containing	contain	VBG	O
quinolone	quinolone	NN	O
benzothiazole	benzothiazole	NN	O
derivative	derivative	JJ	O
46	46	CD	O
and	and	CC	O
the	the	DT	O
nitrobenzylidene	nitrobenzylidene	NN	O
quinolone	quinolone	NNP	O
derivative	derivative	JJ	O
47	47	CD	O
.	.	.	O

Sarkar	Sarkar	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

prepared	prepared	NNP	O
benzothiazolyl	benzothiazolyl	NNP	O
quinoline	quinoline	NNP	O
derivatives	derivative	NNS	O
by	by	IN	O
treatment	treatment	NN	O
of	of	IN	O
2-aminobenzothiol	2-aminobenzothiol	CD	O
with	with	IN	O
2-hydroxy	2-hydroxy	CD	O
-	-	HYPH	O
benzaldehyde	benzaldehyde	NN	O
and	and	CC	O
studied	study	VBD	O
their	-PRON-	PRP$	O
activities	activity	NNS	O
for	for	IN	O
the	the	DT	O
A1	A1	NNP	O
,	,	,	O
A2A	A2A	NNP	O
,	,	,	O
A2B	A2B	NNP	O
and	and	CC	O
A3	A3	NNP	O
adenosine	adenosine	NN	O
receptors	receptor	NNS	O
.	.	.	O

The	the	DT	O
A3	A3	NNP	O
receptor	receptor	NN	O
is	be	VBZ	O
overexpressed	overexpresse	VBN	O
in	in	IN	O
different	different	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

The	the	DT	O
quinolone	quinolone	NN	O
based	base	VBD	O
derivative	derivative	JJ	O
48	48	CD	O
showed	show	VBD	O
the	the	DT	O
maximum	maximum	JJ	O
potency	potency	NN	O
for	for	IN	O
the	the	DT	O
hA3	hA3	NNP	O
adenosine	adenosine	NN	O
receptor	receptor	NN	B
.	.	.	O

Quinolone	quinolone	NN	O
based	base	VBD	O
benzothiazole	benzothiazole	NN	O
derivative	derivative	JJ	O
48	48	CD	O
.	.	.	O

Tay	Tay	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBD	O
and	and	CC	O
evaluated	evaluate	VBD	O
N-[4-phenyl]-2-aryloxyacetamide	N-[4-phenyl]-2-aryloxyacetamide	NNP	O
derivatives	derivative	NNS	O
for	for	IN	O
cytotoxicity	cytotoxicity	NN	O
and	and	CC	O
anticancer	anticancer	NN	O
activity	activity	NN	O
against	against	IN	O
sixty	sixty	CD	O
human	human	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
derived	derive	VBN	O
from	from	IN	O
9	9	CD	O
neoplastic	neoplastic	JJ	O
diseases	disease	NNS	O
,	,	,	O
among	among	IN	O
which	which	WDT	O
L	L	NNP	O
,	,	,	O
M	M	NNP	O
,	,	,	O
RC	RC	NNP	O
NSCLC	NSCLC	NNP	O
CC	cc	NN	O
,	,	,	O
OC	OC	NNP	O
,	,	,	O
BC	BC	NNP	O
,	,	,	O
CNSC	CNSC	NNP	O
and	and	CC	O
PC	PC	NNP	O
.	.	.	O

Derivatives	Derivatives	NNP	O
49	49	CD	O
N-(4-(benzothiazol-2-yl)-3-methoxyphenyl)-3âpropanamide	N-(4-(benzothiazol-2-yl)-3-methoxyphenyl)-3âpropanamide	NNP	O
and	and	CC	O
50	50	CD	O
N-(4-(benzothiazol-2-yl)-2-chlorophenyl)-2âacetamide	n-(4-(benzothiazol-2-yl)-2-chlorophenyl)-2âacetamide	NN	O
exhibited	exhibit	VBD	O
interesting	interesting	JJ	O
anti	anti	JJ	O
-	-	JJ	O
cancer	cancer	JJ	O
activities	activity	NNS	O
.	.	.	O

The	the	DT	O
SAR	SAR	NNP	O
studies	study	NNS	O
investigated	investigate	VBD	O
that	that	IN	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
of	of	IN	O
these	these	DT	O
compounds	compound	NNS	O
were	be	VBD	O
due	due	JJ	O
to	to	IN	O
the	the	DT	O
substitutions	substitution	NNS	O
present	present	JJ	O
in	in	IN	O
their	-PRON-	PRP$	O
molecules	molecule	NNS	B
.	.	.	O

Substituted	substitute	VBN	O
propanamide	propanamide	NN	O
/	/	SYM	O
acetamide	acetamide	NN	O
based	base	VBN	O
benzothiazoles	benzothiazoles	NNP	O
49	49	CD	O
and	and	CC	O
50	50	CD	O
.	.	.	O

Noolvi	noolvi	CC	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
chloro	chloro	NN	O
substituted	substitute	VBN	O
benzothiazole	benzothiazole	NN	O
amines	amine	NNS	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
produce	produce	VB	O
isothiocyanates	isothiocyanate	NNS	O
and	and	CC	O
thioureases	thiourease	NNS	O
.	.	.	O

These	these	DT	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
were	be	VBD	O
tested	test	VBN	O
for	for	IN	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
.	.	.	O

The	the	DT	O
dichlorophenyl	dichlorophenyl	NN	O
containing	contain	VBG	O
chlorobenzothiazole	chlorobenzothiazole	NNP	O
51	51	CD	O
showed	show	VBD	O
good	good	JJ	O
anticancer	anticancer	NN	O
activity	activity	NN	O
against	against	IN	O
9	9	CD	O
different	different	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
having	have	VBG	O
GI50	GI50	NNP	O
values	value	NNS	O
in	in	IN	O
the	the	DT	O
range	range	NN	O
of	of	IN	O
1.60âÂµMâ71.8ânM.	1.60ââµmâ71.8ânm.	CD	O
The	the	DT	O
derivative	derivative	JJ	O
51	51	CD	O
exhibited	exhibit	VBN	O
GI50	gi50	NN	O
=	=	SYM	O
7.18âÃâ10â8âM	7.18âãâ10â8âm	CD	O
against	against	IN	O
non	non	JJ	O
-	-	JJ	O
small	small	JJ	O
cell	cell	NN	O
lung	lung	NN	O
cancer	cancer	NN	O
.	.	.	O

The	the	DT	O
SAR	SAR	NNP	O
studies	study	NNS	O
showed	show	VBD	O
that	that	IN	O
the	the	DT	O
highest	high	JJS	O
activity	activity	NN	O
of	of	IN	O
compound	compound	NN	O
51	51	CD	O
was	be	VBD	O
due	due	JJ	O
to	to	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
three	three	CD	O
chlorine	chlorine	NN	O
atoms	atom	NNS	O
in	in	IN	O
the	the	DT	O
compound	compound	NN	O
as	as	IN	O
compared	compare	VBN	O
to	to	IN	O
other	other	JJ	O
derivatives	derivative	NNS	B
.	.	.	O

Havrylyuk	havrylyuk	NN	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

screened	screen	VBD	O
novel	novel	JJ	O
4-thiazolidinone	4-thiazolidinone	CD	O
benzothiazole	benzothiazole	NN	O
derivatives	derivative	NNS	O
against	against	IN	O
ovarian	ovarian	JJ	O
,	,	,	O
renal	renal	JJ	O
,	,	,	O
prostate	prostate	NN	O
,	,	,	O
leukaemia	leukaemia	NN	O
,	,	,	O
melanoma	melanoma	NNP	O
,	,	,	O
lung	lung	NN	O
,	,	,	O
colon	colon	NN	O
,	,	,	O
CNS	cns	NN	O
and	and	CC	O
breast	breast	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

The	the	DT	O
thioxothiazolidine	thioxothiazolidine	NN	O
acetamide	acetamide	NN	O
benzothiazole	benzothiazole	NNP	O
52	52	CD	O
showed	show	VBD	O
the	the	DT	O
most	most	RBS	O
promising	promising	JJ	O
anti	anti	JJ	O
-	-	JJ	O
cancer	cancer	JJ	O
activity	activity	NN	O
.	.	.	O

The	the	DT	O
SAR	SAR	NNP	O
studies	study	NNS	O
pinpointed	pinpoint	VBD	O
that	that	IN	O
the	the	DT	O
introduction	introduction	NN	O
of	of	IN	O
4-chloro	4-chloro	CD	O
-	-	HYPH	O
phenoxy	phenoxy	NN	O
-	-	HYPH	O
N	n	NN	O
--	--	:	O
acetamide	acetamide	NN	O
substitutions	substitution	NNS	O
on	on	IN	O
position	position	NN	O
5	5	CD	O
of	of	IN	O
the	the	DT	O
4-thiazolidinones	4-thiazolidinones	CD	O
ring	ring	NN	O
enhanced	enhance	VBD	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
cancer	cancer	JJ	O
potential	potential	JJ	B
.	.	.	O

Substituted	substitute	VBN	O
thioxothiazolidine	thioxothiazolidine	NN	O
acetamide	acetamide	NN	O
benzothiazole	benzothiazole	NNP	O
derivative	derivative	JJ	O
52	52	CD	O
.	.	.	O

Prabhu	Prabhu	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBD	O
and	and	CC	O
studied	study	VBD	O
the	the	DT	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
of	of	IN	O
oxothiazolidine	oxothiazolidine	NN	O
based	base	VBN	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
.	.	.	O

The	the	DT	O
substituted	substitute	VBN	O
chlorophenyl	chlorophenyl	NN	O
oxothiazolidine	oxothiazolidine	NNP	O
based	base	VBN	O
benzothiazole	benzothiazole	NNP	O
53	53	CD	O
showed	show	VBD	O
the	the	DT	O
most	most	RBS	O
effective	effective	JJ	O
anticancer	anticancer	NN	O
activity	activity	NN	O
against	against	IN	O
HeLa	HeLa	NNP	O
cell	cell	NN	O
line	line	NN	O
,	,	,	O
inducing	induce	VBG	O
96.8	96.8	CD	O
%	%	NN	O
inhibition	inhibition	NN	O
and	and	CC	O
IC50	IC50	NNP	O
value	value	NN	O
of	of	IN	O
9.76âÂµM	9.76âÂµM	NNP	O
,	,	,	O
when	when	WRB	O
compared	compare	VBN	O
with	with	IN	O
the	the	DT	O
reference	reference	NN	O
drug	drug	NN	O
cisplatin	cisplatin	NN	B
.	.	.	O

Oxothiazolidine	Oxothiazolidine	NNP	O
based	base	VBD	O
benzothiazole	benzothiazole	JJ	O
derivative	derivative	JJ	O
53	53	CD	O
and	and	CC	O
thiazolidine	thiazolidine	NN	O
benzothiazole	benzothiazole	NN	O
derivative	derivative	JJ	O
54	54	CD	O
.	.	.	O

Abdelgawad	Abdelgawad	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBD	O
thiazolidinone	thiazolidinone	NN	O
containing	contain	VBG	O
benzoxazole	benzoxazole	JJ	O
derivatives	derivative	NNS	O
by	by	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
aminobenzoic	aminobenzoic	NNP	O
acid	acid	NN	O
with	with	IN	O
substituted	substitute	VBN	O
aniline	aniline	NN	O
that	that	WDT	O
further	further	RB	O
reacted	react	VBD	O
in	in	IN	O
different	different	JJ	O
steps	step	NNS	O
under	under	IN	O
specific	specific	JJ	O
conditions	condition	NNS	O
to	to	TO	O
afford	afford	VB	O
final	final	JJ	O
product	product	NN	O
and	and	CC	O
studied	study	VBD	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
against	against	IN	O
breast	breast	NN	O
cancer	cancer	NN	O
and	and	CC	O
liver	liver	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

Among	among	IN	O
all	all	PDT	O
these	these	DT	O
derivatives	derivative	NNS	O
,	,	,	O
nitrobenzylidene	nitrobenzylidene	NN	O
containing	contain	VBG	O
thiazolidine	thiazolidine	NN	O
derivative	derivative	JJ	O
54	54	CD	O
exhibited	exhibit	VBD	O
some	some	DT	O
anticancer	anticancer	NN	O
activity	activity	NN	O
,	,	,	O
with	with	IN	O
an	an	DT	O
IC50	IC50	NNP	O
value	value	NN	O
of	of	IN	O
36ânM	36ânm	CD	O
and	and	CC	O
48ânM	48ânm	CD	O
against	against	IN	O
MCF7	MCF7	NNP	O
and	and	CC	O
HEPG2	HEPG2	NNP	O
,	,	,	O
respectively	respectively	RB	B
.	.	.	O

Ma	Ma	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
indole	indole	NNP	O
based	base	VBN	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
and	and	CC	O
studied	study	VBD	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
.	.	.	O

Among	among	IN	O
all	all	PDT	O
these	these	DT	O
derivatives	derivative	NNS	O
,	,	,	O
the	the	DT	O
chlorobenzyl	chlorobenzyl	NNP	O
indole	indole	NNP	O
semicarbazide	semicarbazide	NNP	O
benzothiazole	benzothiazole	NNP	O
55	55	CD	O
exhibited	exhibit	VBN	O
anticancer	anticancer	NN	O
activity	activity	NN	O
against	against	IN	O
four	four	CD	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
such	such	JJ	O
as	as	IN	O
HT-29	HT-29	NNP	O
,	,	,	O
H460	H460	NNP	O
,	,	,	O
A549	A549	NNP	O
and	and	CC	O
MDA	MDA	NNP	O
-	-	HYPH	O
MB-231	MB-231	NNP	O
.	.	.	O

Derivative	derivative	JJ	O
55	55	CD	O
showed	show	VBD	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
0.024âÂµM	0.024ââµm	NN	O
for	for	IN	O
HT-29	HT-29	NNP	O
,	,	,	O
0.29âÂµM	0.29âÂµM	NNP	O
for	for	IN	O
H460	H460	NNP	O
,	,	,	O
0.84âÂµM	0.84âÂµM	NNP	O
for	for	IN	O
A549	A549	NNP	O
and	and	CC	O
0.88âÂµM	0.88âÂµM	NNP	O
for	for	IN	O
MDA	MDA	NNP	O
-	-	HYPH	O
MB-231	MB-231	NNP	O
,	,	,	O
respectively	respectively	RB	B
.	.	.	O

Chlorobenzyl	Chlorobenzyl	NNP	O
indole	indole	RB	O
semicarbazide	semicarbazide	VBP	O
BTA	BTA	NNP	O
derivative	derivative	JJ	O
55	55	CD	O
and	and	CC	O
urea	urea	NNP	O
BTA	BTA	NNP	O
derivative	derivative	JJ	O
56	56	CD	O
.	.	.	O

Xie	Xie	NNS	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

prepared	prepared	NNP	O
substituted	substitute	VBD	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
and	and	CC	O
studied	study	VBD	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
.	.	.	O

Among	among	IN	O
all	all	DT	O
derivatives	derivative	NNS	O
,	,	,	O
the	the	DT	O
urea	urea	NNP	O
benzothiazole	benzothiazole	NNP	O
56	56	CD	O
exhibited	exhibit	VBD	O
interesting	interesting	JJ	O
antitumor	antitumor	NN	O
activity	activity	NN	O
against	against	IN	O
60	60	CD	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

The	the	DT	O
average	average	JJ	O
GI50	GI50	NNP	O
value	value	NN	O
for	for	IN	O
derivative	derivative	JJ	O
56	56	CD	O
was	be	VBD	O
0.38âÂµM	0.38âÂµM	NNP	B
.	.	.	O

Uremis	Uremis	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBD	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
using	use	VBG	O
substituted	substituted	JJ	O
aldehyde	aldehyde	NN	O
with	with	IN	O
bicyclohept-2-en-6-one	bicyclohept-2-en-6-one	NNP	O
.	.	.	O

The	the	DT	O
nitro	nitro	NNP	O
-	-	HYPH	O
styryl	styryl	NNP	O
containing	contain	VBG	O
benzothiazole	benzothiazole	NNP	O
derivative	derivative	JJ	O
57	57	CD	O
and	and	CC	O
the	the	DT	O
fluorostyryl	fluorostyryl	NNP	O
benzothiazole	benzothiazole	NNP	O
derivative	derivative	NNP	O
58	58	CD	O
were	be	VBD	O
reported	report	VBN	O
for	for	IN	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activity	activity	NN	O
against	against	IN	O
pancreatic	pancreatic	JJ	O
cancer	cancer	NN	O
cells	cell	NNS	O
having	have	VBG	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
27âÂ±â0.24âÂµM	27ââ±â0.24ââµm	CD	O
for	for	IN	O
57	57	CD	O
and	and	CC	O
of	of	IN	O
35âÂ±â0.51âÂµM	35ââ±â0.51ââµm	CD	O
for	for	IN	O
derivative	derivative	JJ	O
58	58	CD	B
.	.	.	O

Nitrostyryl	Nitrostyryl	NNP	O
containing	contain	VBG	O
BTA	BTA	NNP	O
derivative	derivative	JJ	O
57	57	CD	O
and	and	CC	O
fluorostyryl	fluorostyryl	NNP	O
BTA	BTA	NNP	O
derivative	derivative	JJ	O
58	58	CD	O
.	.	.	O

Cindric	cindric	JJ	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

obtained	obtain	VBD	O
carboxamide	carboxamide	NN	O
containing	contain	VBG	O
benzothiazole	benzothiazole	RB	O
by	by	IN	O
the	the	DT	O
condensation	condensation	NN	O
of	of	IN	O
substituted	substitute	VBN	O
thiophenes	thiophene	NNS	O
and	and	CC	O
substituted	substitute	VBN	O
amino	amino	NN	O
-	-	:	O
BTAs	bta	NNS	O
to	to	TO	O
prepare	prepare	VB	O
the	the	DT	O
desired	desire	VBN	O
product	product	NN	O
and	and	CC	O
studied	study	VBD	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activity	activity	NN	O
against	against	IN	O
MCF-7	mcf-7	JJ	O
cell	cell	NN	O
line	line	NN	O
.	.	.	O

The	the	DT	O
benzothiophene	benzothiophene	NN	O
based	base	VBN	O
carboxamide	carboxamide	NNP	O
chloroaminobenzothiazole	chloroaminobenzothiazole	NN	O
59	59	CD	O
exhibited	exhibit	VBN	O
potent	potent	JJ	O
anticancer	anticancer	NN	O
activity	activity	NN	O
with	with	IN	O
an	an	DT	O
IC50	IC50	NNP	O
of	of	IN	O
40ânM	40ânm	CD	B
.	.	.	O

Benzothiophene	Benzothiophene	NNS	O
carboxamide	carboxamide	NN	O
chloroaminobenzothiazole	chloroaminobenzothiazole	NN	O
derivative	derivative	JJ	O
59	59	CD	O
.	.	.	O

Nikolova	Nikolova	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

obtained	obtain	VBD	O
Rucomplexes	Rucomplexes	NNP	O
containing	contain	VBG	O
benzothiazole	benzothiazole	NN	O
derivatives	derivative	NNS	O
and	and	CC	O
tested	test	VBD	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activity	activity	NN	O
against	against	IN	O
K-562	K-562	NNP	O
and	and	CC	O
KE-37	KE-37	NNP	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

Among	among	IN	O
all	all	PDT	O
these	these	DT	O
derivatives	derivative	NNS	O
,	,	,	O
the	the	DT	O
Rucontaining	rucontaining	NN	O
methylbenzothiazole	methylbenzothiazole	NN	O
60	60	CD	O
exhibited	exhibit	VBD	O
the	the	DT	O
highest	high	JJS	O
cytotoxic	cytotoxic	NN	O
activity	activity	NN	O
against	against	IN	O
K-562	K-562	NNP	O
and	and	CC	O
KE-37	KE-37	NNP	O
,	,	,	O
having	have	VBG	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
7.74âÂ±â2.50	7.74âÂ±â2.50	NNP	O
for	for	IN	O
KE-37	KE-37	NNP	O
and	and	CC	O
of	of	IN	O
16.21âÂ±â2.33	16.21ââ±â2.33	CD	O
for	for	IN	O
K-562	K-562	NNP	O
when	when	WRB	O
compared	compare	VBN	O
with	with	IN	O
the	the	DT	O
standard	standard	JJ	O
drug	drug	NN	O
cisplatin	cisplatin	NN	B
.	.	.	O

Rucontaining	rucontaine	VBG	O
methylbenzothiazole	methylbenzothiazole	NN	O
derivative	derivative	JJ	O
60	60	CD	O
.	.	.	O

Yurttas	Yurttas	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

obtained	obtain	VBD	O
benzothiazole	benzothiazole	NN	O
derivatives	derivative	NNS	O
by	by	IN	O
acetylation	acetylation	NN	O
of	of	IN	O
substituted	substituted	JJ	O
benzothiazole	benzothiazole	NN	O
with	with	IN	O
chloroacetyl	chloroacetyl	NN	O
chloride	chloride	NN	O
that	that	WDT	O
was	be	VBD	O
further	further	RB	O
treated	treat	VBN	O
in	in	IN	O
series	series	NN	O
of	of	IN	O
reactions	reaction	NNS	O
to	to	TO	O
obtain	obtain	VB	O
specific	specific	JJ	O
derivatives	derivative	NNS	O
which	which	WDT	O
were	be	VBD	O
tested	test	VBN	O
for	for	IN	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
against	against	IN	O
lung	lung	NN	O
carcinoma	carcinoma	NN	O
cell	cell	NN	O
line	line	NN	O
.	.	.	O

Derivatives	derivative	NNS	O
61	61	CD	O
and	and	CC	O
derivative	derivative	JJ	O
62	62	CD	O
exhibited	exhibit	VBD	O
good	good	JJ	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
against	against	IN	O
A549	A549	NNP	O
with	with	IN	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
10.67âÂ±â2.02	10.67ââ±â2.02	CD	O
Âµg	Âµg	NNP	O
/	/	SYM	O
mL	mL	NNP	O
and	and	CC	O
9.0âÂ±â1.0	9.0ââ±â1.0	CD	O
Âµg	Âµg	NNP	O
/	/	SYM	O
mL	mL	NNP	O
respectively	respectively	RB	O
as	as	IN	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
reference	reference	NN	O
compound	compound	NN	O
cisplatin	cisplatin	NN	B
.	.	.	O

Benzimidazole	Benzimidazole	NNP	O
based	base	VBN	O
acetamide	acetamide	NN	O
methoxybenzothiazole	methoxybenzothiazole	NN	O
derivative	derivative	JJ	O
61	61	CD	O
and	and	CC	O
acetamide	acetamide	NNP	O
ethoxybenzothiazole	ethoxybenzothiazole	NNP	O
derivative	derivative	JJ	O
62	62	CD	O
.	.	.	O

Oanh	Oanh	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
hydroxamic	hydroxamic	JJ	O
acids	acid	NNS	O
containing	contain	VBG	O
benzothiazole	benzothiazole	RB	O
by	by	IN	O
the	the	DT	O
reaction	reaction	NN	O
of	of	IN	O
2-aminobenzothiazole	2-aminobenzothiazole	CD	O
with	with	IN	O
adipic	adipic	JJ	O
acid	acid	NN	O
to	to	TO	O
produce	produce	VB	O
esters	ester	NNS	O
that	that	WDT	O
were	be	VBD	O
converted	convert	VBN	O
into	into	IN	O
the	the	DT	O
desired	desire	VBN	O
BTA	BTA	NNP	O
hydroxamates	hydroxamate	NNS	O
,	,	,	O
and	and	CC	O
tested	test	VBN	O
for	for	IN	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
against	against	IN	O
five	five	CD	O
different	different	JJ	O
cell	cell	NN	O
lines	line	NNS	O
such	such	JJ	O
MCF-7	MCF-7	NNP	O
,	,	,	O
AsPC-1	aspc-1	ADD	O
,	,	,	O
SW620	SW620	NNP	O
,	,	,	O
PC3	PC3	NNP	O
and	and	CC	O
NCI	NCI	NNP	O
-	-	HYPH	O
H460	H460	NNP	O
.	.	.	O

Among	among	IN	O
the	the	DT	O
synthesised	synthesise	VBN	O
derivatives	derivative	NNS	O
,	,	,	O
hydroxamic	hydroxamic	JJ	O
acids	acid	NNS	O
63	63	CD	O
and	and	CC	O
64	64	CD	O
exhibited	exhibit	VBN	O
good	good	JJ	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
,	,	,	O
with	with	IN	O
the	the	DT	O
average	average	JJ	O
IC50	IC50	NNP	O
value	value	NN	O
of	of	IN	O
0.81âÂµg	0.81âÂµg	NNP	O
/	/	SYM	O
mL	mL	NNP	O
and	and	CC	O
1.28âÂµg	1.28âÂµg	NNP	O
/	/	SYM	O
mL	ml	NN	O
respectively	respectively	RB	B
.	.	.	O

Hydroxamic	hydroxamic	JJ	O
acid	acid	NN	O
containing	contain	VBG	O
methyl	methyl	NN	O
/	/	SYM	O
methoxy	methoxy	NNP	O
benzothiazole	benzothiazole	NN	O
scaffolds	scaffold	VBZ	O
63	63	CD	O
and	and	CC	O
64	64	CD	O
.	.	.	O

Rodrigues	rodrigue	NNS	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBN	O
carbohydrazide	carbohydrazide	NN	O
containing	contain	VBG	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
and	and	CC	O
studied	study	VBD	O
their	-PRON-	PRP$	O
antitumor	antitumor	NN	O
activities	activity	NNS	O
against	against	IN	O
human	human	JJ	O
prostate	prostate	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

Nâ²-formyl-2âbenzothiazole-6-carbohydrazide	nâ²-formyl-2âbenzothiazole-6-carbohydrazide	CD	O
65	65	CD	O
exhibited	exhibit	VBN	O
potent	potent	JJ	O
anticancer	anticancer	NN	O
activity	activity	NN	O
against	against	IN	O
PC-3	PC-3	NNP	O
and	and	CC	O
LNCaP	lncap	NN	O
having	have	VBG	O
IC50	IC50	NNP	O
values	value	NNS	O
19.9âÂ±â1.17	19.9ââ±â1.17	CD	O
and	and	CC	O
11.2âÂ±â0.79âÂµg	11.2ââ±â0.79ââµg	NN	O
/	/	SYM	O
m	m	NNP	O
respectively	respectively	RB	B
.	.	.	O

Derivative	derivative	JJ	O
65â67	65â67	NN	O
discussed	discuss	VBD	O
in	in	IN	O
the	the	DT	O
article	article	NN	O
.	.	.	O

Rao	rao	JJ	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reportyed	reportyed	NNP	O
DNA	DNA	NNP	O
-	-	HYPH	O
intercalating	intercalating	NN	O
naphthalimide	naphthalimide	IN	O
-	-	HYPH	O
benzothiazole	benzothiazole	NN	O
derivatives	derivative	NNS	O
and	and	CC	O
evaluated	evaluate	VBD	O
their	-PRON-	PRP$	O
cytotoxicities	cytotoxicity	NNS	O
against	against	IN	O
three	three	CD	O
different	different	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
such	such	JJ	O
as	as	IN	O
HT29	HT29	NNP	O
,	,	,	O
A549	A549	NNP	O
and	and	CC	O
MCF-7	MCF-7	NNP	O
.	.	.	O

Among	among	IN	O
all	all	DT	O
tested	test	VBN	O
derivatives	derivative	NNS	O
,	,	,	O
the	the	DT	O
naphthalimide	naphthalimide	JJ	O
derivative	derivative	JJ	O
66	66	CD	O
possessed	possess	VBD	O
good	good	JJ	O
antitumor	antitumor	NN	O
activity	activity	NN	O
against	against	IN	O
HT-29	HT-29	NNP	O
,	,	,	O
A549	A549	NNP	O
and	and	CC	O
MCF-7	mcf-7	JJ	O
cell	cell	NN	O
lines	line	NNS	O
having	have	VBG	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
3.72âÂ±â0.3âÂµM	3.72ââ±â0.3ââµm	CD	O
,	,	,	O
4.074âÂ±â0.3âÂµM	4.074ââ±â0.3ââµm	CD	O
and	and	CC	O
07.91âÂ±â0.4âÂµM	07.91ââ±â0.4ââµm	CD	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
naphthalimide	naphthalimide	JJ	O
67	67	CD	O
showed	show	VBD	O
antitumor	antitumor	NN	O
activity	activity	NN	O
with	with	IN	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
03.47âÂ±â0.2âÂµM	03.47âÂ±â0.2âÂµM	NNS	O
for	for	IN	O
HT-29	HT-29	NNP	O
,	,	,	O
03.89âÂ±â0.3âÂµM	03.89ââ±â0.3ââµm	CD	O
for	for	IN	O
A549	A549	NNP	O
and	and	CC	O
05.08âÂ±â0.3âÂµM	05.08âÂ±â0.3âÂµM	NNS	O
for	for	IN	O
MCF-7	mcf-7	JJ	O
cell	cell	NN	O
lines	line	NNS	B
.	.	.	O

Rao	rao	JJ	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

reported	report	VBD	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
2-arylaminobenzothiazole	2-arylaminobenzothiazole	CD	O
-	-	HYPH	O
arylpropeonones	arylpropeonone	NNS	O
and	and	CC	O
studied	study	VBD	O
their	-PRON-	PRP$	O
cytotoxic	cytotoxic	JJ	O
activities	activity	NNS	O
against	against	IN	O
different	different	JJ	O
human	human	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

Among	among	IN	O
all	all	DT	O
synthesised	synthesise	VBN	O
derivatives	derivative	NNS	O
,	,	,	O
substituted	substitute	VBD	O
phenylamino	phenylamino	RB	O
based	base	VBN	O
methoxybenzothiazole	methoxybenzothiazole	NN	O
68	68	CD	O
and	and	CC	O
substituted	substitute	VBD	O
phenylamino	phenylamino	NNP	O
based	base	VBN	O
methoxy	methoxy	NNP	O
methylbenzothiazole	methylbenzothiazole	NNP	O
69	69	CD	O
showed	show	VBD	O
potent	potent	JJ	O
cytotoxic	cytotoxic	JJ	O
activity	activity	NN	O
against	against	IN	O
HeLa	HeLa	NNP	O
cell	cell	NN	O
lines	line	NNS	O
possessing	possess	VBG	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
0.5âÂ±â0.02	0.5ââ±â0.02	CD	O
and	and	CC	O
0.6âÂ±â0.29âÂµM	0.6ââ±â0.29ââµm	CD	B
.	.	.	O

Substituted	substitute	VBN	O
phenylamino	phenylamino	NN	O
based	base	VBN	O
methoxy	methoxy	NN	O
benzothiazoles	benzothiazole	NNS	O
68	68	CD	O
and	and	CC	O
69	69	CD	O
.	.	.	O

Osmaniye	osmaniye	NN	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

synthesised	synthesise	VBN	O
benzothiazole	benzothiazole	JJ	O
-	-	HYPH	O
thiazolidine	thiazolidine	NN	O
derivatives	derivative	NNS	O
and	and	CC	O
studied	study	VBD	O
their	-PRON-	PRP$	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
against	against	IN	O
C6	C6	NNP	O
and	and	CC	O
healthy	healthy	JJ	O
NIH3T3	NIH3T3	NNP	O
cell	cell	NN	O
lines	line	NNS	O
.	.	.	O

Among	among	IN	O
the	the	DT	O
synthesised	synthesise	VBN	O
derivatives	derivative	NNS	O
,	,	,	O
substituted	substitute	VBD	O
phenylthizolidene	phenylthizolidene	NN	O
based	base	VBN	O
benzothiazole	benzothiazole	NNP	O
70	70	CD	O
and	and	CC	O
substituted	substitute	VBD	O
nitrophenylthizolidene	nitrophenylthizolidene	NNP	O
benzothiazole	benzothiazole	NNP	O
71	71	CD	O
exhibited	exhibit	VBD	O
some	some	DT	O
cytotoxic	cytotoxic	JJ	O
activities	activity	NNS	O
against	against	IN	O
C6	C6	NNP	O
cell	cell	NN	O
line	line	NN	O
showing	show	VBG	O
IC50	IC50	NNP	O
value	value	NN	O
0.03âmM.	0.03âmM.	NNP	O
The	the	DT	O
SAR	SAR	NNP	O
studies	study	NNS	O
showed	show	VBD	O
that	that	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
a	a	DT	O
phenyl	phenyl	NNP	O
group	group	NN	O
on	on	IN	O
the	the	DT	O
thiazolidine	thiazolidine	NN	O
part	part	NN	O
of	of	IN	O
the	the	DT	O
structure	structure	NN	O
increased	increase	VBD	O
the	the	DT	O
selectivity	selectivity	NN	O
while	while	IN	O
substitution	substitution	NN	O
with	with	IN	O
an	an	DT	O
electron	electron	NN	O
withdrawing	withdraw	VBG	O
or	or	CC	O
donating	donate	VBG	O
groups	group	NNS	O
decreased	decrease	VBD	O
the	the	DT	O
selectivity	selectivity	NN	B
.	.	.	O

Substituted	substitute	VBN	O
phenylthizolidene	phenylthizolidene	NN	O
based	base	VBN	O
benzothiazole	benzothiazole	JJ	O
derivative	derivative	JJ	O
70	70	CD	O
and	and	CC	O
71	71	CD	O
.	.	.	O

Carbonic	carbonic	JJ	O
anhydrases	anhydrase	NNS	O
are	be	VBP	O
zinc	zinc	NN	O
enzymes	enzyme	NNS	O
which	which	WDT	O
catalyse	catalyse	VBP	O
the	the	DT	O
reversible	reversible	JJ	O
interconversion	interconversion	NN	O
between	between	IN	O
CO2	CO2	NNP	O
and	and	CC	O
bicarbonate	bicarbonate	JJ	B
.	.	.	O

CO2	CO2	NNP	O
is	be	VBZ	O
efficiently	efficiently	RB	O
hydrated	hydrate	VBN	O
through	through	IN	O
a	a	DT	O
zinc	zinc	NN	O
hydroxide	hydroxide	NN	O
intermediate	intermediate	JJ	O
from	from	IN	O
the	the	DT	O
enzyme	enzyme	NNS	O
active	active	JJ	O
site	site	NN	O
with	with	IN	O
generation	generation	NN	O
of	of	IN	O
the	the	DT	O
weak	weak	JJ	O
base	base	NN	O
bicarbonate	bicarbonate	NN	O
and	and	CC	O
the	the	DT	O
strong	strong	JJ	O
acid	acid	NN	O
H+	H+	NNP	O
.	.	.	O

As	as	IN	O
a	a	DT	O
consequence	consequence	NN	O
,	,	,	O
CAs	ca	NNS	O
are	be	VBP	O
involved	involve	VBN	O
in	in	IN	O
pH	pH	NNP	O
regulation	regulation	NN	O
,	,	,	O
electrolyte	electrolyte	NNP	O
secretion	secretion	NN	O
and	and	CC	O
metabolism	metabolism	NN	O
,	,	,	O
in	in	IN	O
normal	normal	JJ	O
and	and	CC	O
tumour	tumour	VB	O
tissues	tissue	NNS	B
.	.	.	O

Fifteen	fifteen	CD	O
Î±-CA	Î±-CA	NNP	O
isoforms	isoform	NNS	O
are	be	VBP	O
present	present	JJ	O
in	in	IN	O
humans	human	NNS	O
,	,	,	O
with	with	IN	O
at	at	RB	O
least	least	RBS	O
two	two	CD	O
of	of	IN	O
tyhem	tyhem	NN	O
overexporessed	overexporesse	VBN	O
in	in	IN	O
hypoxic	hypoxic	JJ	O
tumours	tumour	NNS	B
,	,	,	B
,	,	,	B
,	,	,	O
as	as	IN	O
a	a	DT	O
consequence	consequence	NN	O
of	of	IN	O
the	the	DT	O
hypoxia	hypoxia	NNP	O
inducible	inducible	JJ	O
factor	factor	NN	O
HIF-1Î±	HIF-1Î±	NNP	O
transcription	transcription	NN	O
factor	factor	NN	O
cascade	cascade	NN	O
activation	activation	NN	B
,	,	,	B
.	.	.	O

CAs	ca	NNS	O
are	be	VBP	O
efficiently	efficiently	RB	O
inhibited	inhibit	VBN	O
by	by	IN	O
a	a	DT	O
range	range	NN	O
of	of	IN	O
compounds	compound	NNS	O
,	,	,	O
such	such	JJ	O
as	as	IN	O
the	the	DT	O
sulphonamides	sulphonamide	NNS	O
and	and	CC	O
their	-PRON-	PRP$	O
isosteres	isostere	NNS	B
,	,	,	O
and	and	CC	O
inorganic	inorganic	JJ	O
anions	anion	NNS	B
,	,	,	O
which	which	WDT	O
constitute	constitute	VBP	O
the	the	DT	O
main	main	JJ	O
zinc	zinc	NN	O
-	-	HYPH	O
binding	bind	VBG	O
CA	CA	NNP	O
inhibitor	inhibitor	NN	O
classes	class	NNS	B
,	,	,	B
,	,	,	B
.	.	.	O

Some	some	DT	O
of	of	IN	O
the	the	DT	O
CAIs	CAIs	NNPS	O
belonging	belong	VBG	O
to	to	IN	O
the	the	DT	O
sulphonamide	sulphonamide	JJ	B
,	,	,	O
sulfocoumarin	sulfocoumarin	NN	B
,	,	,	O
saccharin	saccharin	NNP	B
or	or	CC	O
other	other	JJ	O
structurally	structurally	RB	O
related	relate	VBN	O
chemotypes	chemotype	NNS	B
,	,	,	B
,	,	,	O
were	be	VBD	O
shown	show	VBN	O
to	to	TO	O
possess	possess	VB	O
significant	significant	JJ	O
antitumor	antitumor	NN	O
effects	effect	NNS	O
,	,	,	O
with	with	IN	O
one	one	CD	O
such	such	JJ	O
derivative	derivative	NN	O
in	in	IN	O
Phase	Phase	NNP	O
I	-PRON-	PRP	O
/	/	SYM	O
IIb	iib	RB	O
clinical	clinical	JJ	O
trials	trial	NNS	O
for	for	IN	O
the	the	DT	O
management	management	NN	O
of	of	IN	O
hypoxic	hypoxic	JJ	O
metastatic	metastatic	JJ	O
tumours	tumour	NNS	B
,	,	,	B
.	.	.	O

Indeed	indeed	RB	O
,	,	,	O
by	by	IN	O
inhibiting	inhibit	VBG	O
the	the	DT	O
tumour	tumour	NN	O
-	-	HYPH	O
associated	associate	VBN	O
isoforms	isoform	NNS	O
CA	CA	NNP	O
IX	IX	NNP	O
and	and	CC	O
XII	XII	NNP	O
,	,	,	O
such	such	JJ	O
CAIs	cai	NNS	O
interfere	interfere	VBP	O
with	with	IN	O
the	the	DT	O
pH	pH	NNP	O
regulation	regulation	NN	O
and	and	CC	O
metabolism	metabolism	NN	O
of	of	IN	O
tumours	tumour	NNS	O
,	,	,	O
leading	lead	VBG	O
to	to	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
growth	growth	NN	O
of	of	IN	O
the	the	DT	O
primary	primary	JJ	O
tumour	tumour	NN	O
,	,	,	O
metastases	metastasis	NNS	O
and	and	CC	O
reducing	reduce	VBG	O
the	the	DT	O
population	population	NN	O
of	of	IN	O
cancer	cancer	NN	O
stem	stem	NN	O
cells	cell	NNS	B
.	.	.	O

As	as	IN	O
a	a	DT	O
consequence	consequence	NN	O
,	,	,	O
many	many	JJ	O
CAIs	cai	NNS	O
belonging	belong	VBG	O
to	to	IN	O
various	various	JJ	O
classes	class	NNS	O
are	be	VBP	O
nowadays	nowadays	RB	O
investigated	investigate	VBN	O
for	for	IN	O
their	-PRON-	PRP$	O
antitumor	antitumor	NN	O
/	/	SYM	O
antimetastatic	antimetastatic	JJ	O
effects	effect	NNS	O
,	,	,	O
including	include	VBG	O
many	many	JJ	O
BTA	BTA	NNP	O
derivatives	derivative	VBZ	B
.	.	.	O

Benzothiazoles	benzothiazole	NNS	O
with	with	IN	O
potent	potent	JJ	O
CA	CA	NNP	O
IX	IX	NNP	O
inhibitory	inhibitory	JJ	O
action	action	NN	B
.	.	.	O

.	.	.	O

Indeed	indeed	RB	O
,	,	,	O
using	use	VBG	O
the	the	DT	O
ethoxzolamide	ethoxzolamide	NN	O
72	72	CD	O
,	,	,	O
a	a	DT	O
CAI	CAI	NNP	O
in	in	IN	O
clinical	clinical	JJ	O
use	use	NN	O
for	for	IN	O
decades	decade	NNS	O
as	as	IN	O
lead	lead	NN	O
molecule	molecule	NN	O
,	,	,	O
a	a	DT	O
multitude	multitude	NN	O
of	of	IN	O
primary	primary	JJ	O
sulphonamides	sulphonamide	NNS	O
e.g.	e.g.	NNP	O
compounds	compound	VBZ	O
73â75	73â75	CD	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
the	the	DT	O
secondary	secondary	JJ	O
siulfonamide	siulfonamide	NN	O
76	76	CD	O
were	be	VBD	O
reported	report	VBN	O
to	to	TO	O
act	act	VB	O
as	as	RB	O
highly	highly	RB	O
efficient	efficient	JJ	O
,	,	,	O
frequently	frequently	RB	O
low	low	JJ	O
nanomolar	nanomolar	JJ	O
inhibitors	inhibitor	NNS	O
against	against	IN	O
the	the	DT	O
tumour	tumour	NN	O
-	-	HYPH	O
associated	associate	VBN	O
isoforms	isoform	NNS	O
CA	CA	NNP	O
IX	IX	NNP	O
and	and	CC	O
XII	XII	NNP	B
.	.	.	O

No	no	DT	O
ex	ex	NN	O
vivo	vivo	NNP	O
or	or	CC	O
inÂ	inâ	JJ	O
vivo	vivo	NN	O
studies	study	NNS	O
are	be	VBP	O
available	available	JJ	O
so	so	RB	O
far	far	RB	O
with	with	IN	O
these	these	DT	O
potent	potent	JJ	O
CA	CA	NNP	O
IX	IX	NNP	O
/	/	SYM	O
XII	XII	NNP	O
inhibitors	inhibitor	NNS	O
,	,	,	O
but	but	CC	O
compounds	compound	NNS	O
belonging	belong	VBG	O
to	to	IN	O
other	other	JJ	O
classes	class	NNS	O
of	of	IN	O
sulphonamides	sulphonamide	NNS	O
were	be	VBD	O
proved	prove	VBN	O
to	to	TO	O
possess	possess	VB	O
significant	significant	JJ	O
antitumor	antitumor	NN	O
effects	effect	NNS	O
inÂ	inÂ	NNP	O
vivo	vivo	NNP	O
when	when	WRB	O
they	-PRON-	PRP	O
act	act	VBP	O
as	as	IN	O
potent	potent	JJ	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
these	these	DT	O
two	two	CD	O
CA	CA	NNP	O
isoforms	isoform	NNS	B
,	,	,	B
.	.	.	O

Thus	thus	RB	O
future	future	JJ	O
studes	stude	NNS	O
may	may	MD	O
address	address	VB	O
this	this	DT	O
issue	issue	NN	O
,	,	,	O
considering	consider	VBG	O
the	the	DT	O
fact	fact	NN	O
that	that	IN	O
the	the	DT	O
BTA	BTA	NNP	O
scaffold	scaffold	NN	O
present	present	JJ	O
in	in	IN	O
these	these	DT	O
compounds	compound	NNS	O
may	may	MD	O
induce	induce	VB	O
interesting	interesting	JJ	O
phisico	phisico	NN	O
-	-	HYPH	O
chemical	chemical	NN	O
and	and	CC	O
pharmacologic	pharmacologic	NN	O
properties	property	NNS	O
to	to	IN	O
the	the	DT	O
CA	CA	NNP	O
IX	IX	NNP	O
/	/	SYM	O
XII	XII	NNP	O
inhibitors	inhibitor	NNS	O
,	,	,	O
of	of	IN	O
which	which	WDT	O
many	many	JJ	O
chemical	chemical	NN	O
families	family	NNS	O
are	be	VBP	O
alredy	alredy	IN	O
reported	report	VBN	B
.	.	.	O

Benzothiazole	Benzothiazole	NNP	O
is	be	VBZ	O
a	a	DT	O
pharmacophore	pharmacophore	NN	O
widely	widely	RB	O
used	use	VBN	O
in	in	IN	O
medicinal	medicinal	JJ	O
chemistry	chemistry	NN	O
.	.	.	O

This	this	DT	O
review	review	NN	O
points	point	VBZ	O
out	out	RP	O
to	to	IN	O
a	a	DT	O
growing	grow	VBG	O
interest	interest	NN	O
in	in	IN	O
the	the	DT	O
development	development	NN	O
of	of	IN	O
lead	lead	NN	O
or	or	CC	O
hybrid	hybrid	JJ	O
structures	structure	NNS	O
bearing	bear	VBG	O
the	the	DT	O
BTA	BTA	NNP	O
moiety	moiety	NN	O
as	as	IN	O
antiproliferative	antiproliferative	JJ	O
and	and	CC	O
anticancer	anticancer	NN	O
agents	agent	NNS	O
.	.	.	O

The	the	DT	O
present	present	JJ	O
work	work	NN	O
describes	describe	VBZ	O
the	the	DT	O
potential	potential	NN	O
of	of	IN	O
BTA	BTA	NNP	O
scaffolds	scaffold	NNS	O
in	in	IN	O
the	the	DT	O
management	management	NN	O
of	of	IN	O
various	various	JJ	O
types	type	NNS	O
of	of	IN	O
cancers	cancer	NNS	O
such	such	JJ	O
as	as	IN	O
ovarian	ovarian	JJ	O
,	,	,	O
prostate	prostate	NN	O
,	,	,	O
central	central	JJ	O
nervous	nervous	JJ	O
system	system	NN	O
,	,	,	O
renal	renal	JJ	O
,	,	,	O
gastric	gastric	JJ	O
,	,	,	O
pancreatic	pancreatic	JJ	O
,	,	,	O
liver	liver	NN	O
,	,	,	O
breast	breast	NN	O
and	and	CC	O
colon	colon	NN	O
cancers	cancer	NNS	O
.	.	.	O

SAR	SAR	NNP	O
studies	study	NNS	O
reaveled	reavele	VBD	O
that	that	IN	O
the	the	DT	O
anticancer	anticancer	NN	O
activity	activity	NN	O
of	of	IN	O
BTA	BTA	NNP	O
scaffolds	scaffold	NNS	O
depends	depend	VBZ	O
upon	upon	IN	O
the	the	DT	O
nature	nature	NN	O
of	of	IN	O
substituents	substituent	NNS	O
present	present	JJ	O
in	in	IN	O
these	these	DT	O
molecules	molecule	NNS	O
,	,	,	O
being	be	VBG	O
multifactorial	multifactorial	NN	O
and	and	CC	O
not	not	RB	O
always	always	RB	O
easy	easy	JJ	O
to	to	TO	O
rationalise	rationalise	VB	O
.	.	.	O

The	the	DT	O
plethora	plethora	NN	O
of	of	IN	O
research	research	NN	O
on	on	IN	O
the	the	DT	O
anticancer	anticancer	NN	O
profile	profile	NN	O
of	of	IN	O
BTA	BTA	NNP	O
derivatives	derivative	NNS	O
mentioned	mention	VBN	O
in	in	IN	O
this	this	DT	O
review	review	NN	O
and	and	CC	O
their	-PRON-	PRP$	O
rationalisation	rationalisation	NN	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
drug	drug	NN	O
targets	target	NNS	O
of	of	IN	O
these	these	DT	O
derivatives	derivative	NNS	O
,	,	,	O
when	when	WRB	O
this	this	DT	O
was	be	VBD	O
possible	possible	JJ	O
,	,	,	O
may	may	MD	O
be	be	VB	O
useful	useful	JJ	O
for	for	IN	O
the	the	DT	O
development	development	NN	O
of	of	IN	O
novel	novel	JJ	O
such	such	JJ	O
agents	agent	NNS	O
.	.	.	O

